Surmodics (SRDX) 10-K 30 Nov 18 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Nov. 26, 2018	Mar. 31, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Trading Symbol	SRDX
Entity Registrant Name	SURMODICS INC
Entity Central Index Key	924,717
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		13,398,036
Entity Public Float			$ 255

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017
Current Assets:
Cash and cash equivalents	$ 23,318	$ 16,534
Restricted cash	350
Available-for-sale securities	41,352	31,802
Accounts receivable, net of allowance for doubtful accounts of $147 and $230 as of September 30, 2018 and 2017, respectively	8,877	7,211
Inventories	4,016	3,516
Income tax receivable	1,152	599
Prepaids and other	2,462	1,221
Total Current Assets	81,527	60,883
Property and equipment, net	30,143	22,942
Deferred income taxes	6,304	4,027
Intangible assets, net	17,683	20,562
Goodwill	27,032	27,282
Other assets	1,446	897
Total Assets	164,135	136,593
Current Liabilities:
Accounts payable	2,546	2,396
Accrued liabilities:
Compensation	5,635	3,822
Accrued other	6,265	1,773
Deferred revenue	9,646	62
Contingent consideration	11,041	1,750
Total Current Liabilities	35,133	9,803
Contingent consideration, less current portion	3,425	13,114
Deferred revenue, less current portion	11,247	181
Other long-term liabilities	5,720	1,938
Total Liabilities	55,525	25,036
Commitments and Contingencies (Note 11)
Stockholders’ Equity:
Series A preferred stock — $.05 par value, 450,000 shares authorized; no shares issued and outstanding
Common stock — $.05 par value, 45,000,000 shares authorized; 13,397,647 and 13,094,988 shares issued and outstanding, as of September 30, 2018 and 2017, respectively	670	655
Additional paid-in capital	7,607	5,413
Accumulated other comprehensive income	2,718	3,417
Retained earnings	97,615	102,072
Total Stockholders’ Equity	108,610	111,557
Total Liabilities and Stockholders’ Equity	$ 164,135	$ 136,593

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 147	$ 230
Series A preferred stock, par value	$ 0.05	$ 0.05
Series A preferred stock, shares authorized	450,000	450,000
Series A preferred stock, shares issued	0	0
Series A preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.05	$ 0.05
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	13,397,647	13,094,988
Common stock, shares outstanding	13,397,647	13,094,988

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Revenue:
Research, development and other	$ 7,959	$ 8,535	$ 7,164
Total revenue	$ 81,336	$ 73,112	$ 71,366
Operating costs and expenses:
Type of Cost, Good or Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Product costs	$ 13,997	$ 11,422	$ 10,908
Research and development	40,973	31,817	18,498
Selling, general and administrative	24,111	20,478	18,000
Acquired in-process research and development	7,888
Acquired intangible asset amortization	2,491	2,419	2,422
Contingent consideration expense (gain)	675	(127)	1,492
Acquisition transaction, integration and other costs			3,187
Total operating costs and expenses	90,135	66,009	54,507
Operating (loss) income	(8,799)	7,103	16,859
Other income (loss):
Investment income, net	851	390	63
Foreign exchange gain (loss)	239	(504)	(481)
Gains on strategic investments and other	177	44	507
Other income (loss)	1,267	(70)	89
(Loss) income before income taxes	(7,532)	7,033	16,948
Income tax benefit (provision)	3,075	(3,107)	(6,963)
Net (loss) income	$ (4,457)	$ 3,926	$ 9,985
Basic net (loss) income per share:	$ (0.34)	$ 0.30	$ 0.77
Diluted net (loss) income per share:	$ (0.34)	$ 0.29	$ 0.76
Weighted average number of shares outstanding:
Basic	13,157	13,153	12,998
Diluted	13,157	13,389	13,219
Product Sales [Member]
Revenue:
Revenue	$ 37,953	$ 32,790	$ 30,999
Royalties and License Fees [Member]
Revenue:
Revenue	$ 35,424	$ 31,787	$ 33,203

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (4,457)	$ 3,926	$ 9,985
Other comprehensive (loss) income:
Unrealized holding (losses) gains on available-for-sale securities, net of tax	(38)	49	(68)
Foreign currency translation adjustments	(661)	2,095	1,336
Other comprehensive (loss) income	(699)	2,144	1,268
Comprehensive (loss) income	$ (5,156)	$ 6,070	$ 11,253

Consolidated Statement of Share

Consolidated Statement of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Retained Earnings [Member]
Beginning balance at Sep. 30, 2015	$ 91,873	$ 647	$ 3,060	$ 5	$ 88,161
Beginning balance, shares at Sep. 30, 2015		12,945,000
Net (loss) income	9,985				9,985
Other comprehensive income (loss), net of tax	1,268			1,268
Issuance of common stock	270	$ 4	266
Issuance of common stock, shares		74,000
Common stock options exercised, net	$ 1,546	$ 10	1,536
Common stock options exercised, net, shares	437,850	196,000
Purchase of common stock to pay employee taxes	$ (1,953)	$ (1)	(1,952)
Purchase of common stock to pay employee taxes, shares		(7,000)
Stock-based compensation	3,844		3,844
Ending balance at Sep. 30, 2016	106,833	$ 660	6,754	1,273	98,146
Ending balance, shares at Sep. 30, 2016		13,208,000
Net (loss) income	3,926				3,926
Other comprehensive income (loss), net of tax	2,144			2,144
Issuance of common stock	348	$ 5	343
Issuance of common stock, shares		99,000
Common stock options exercised, net	$ 96	$ 1	95
Common stock options exercised, net, shares	6,819	7,000
Stock Repurchased During Period Value	$ (4,702)	$ (10)	(4,692)
Common stock repurchased, shares	(196,190)	(196,000)
Purchase of common stock to pay employee taxes	$ (560)	$ (1)	(559)
Purchase of common stock to pay employee taxes, shares		(23,000)
Stock-based compensation	3,472		3,472
Ending balance at Sep. 30, 2017	111,557	$ 655	5,413	3,417	102,072
Ending balance, shares at Sep. 30, 2017		13,095,000
Net (loss) income	(4,457)				(4,457)
Other comprehensive income (loss), net of tax	(699)			(699)
Issuance of common stock	340	$ 7	333
Issuance of common stock, shares		137,000
Common stock options exercised, net	$ 1,749	$ 22	1,727
Common stock options exercised, net, shares	450,495	440,000
Purchase of common stock to pay employee taxes	$ (4,687)	$ (14)	(4,673)
Purchase of common stock to pay employee taxes, shares		(274,000)
Stock-based compensation	4,807		4,807
Ending balance at Sep. 30, 2018	$ 108,610	$ 670	$ 7,607	$ 2,718	$ 97,615
Ending balance, shares at Sep. 30, 2018		13,398,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Operating Activities:
Net (loss) income	$ (4,457)	$ 3,926	$ 9,985
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	6,431	5,555	4,873
Stock-based compensation	4,807	3,472	3,844
Contingent consideration expense (gain)	675	(127)	1,492
Unrealized foreign exchange (gain) loss	(148)	474	444
Acquired in-process research and development	7,888
Deferred taxes	(2,277)	1,000	261
Gains on strategic investments	(177)	(43)	(514)
Provision for bad debts	85	208
Impairment losses on intangible assets		427
Property and equipment disposal (gain) loss		6	(66)
Other, net	45		13
Change in operating assets and liabilities
Accounts receivable	(1,773)	(528)	911
Inventories	(513)	97	(143)
Prepaids and other	(1,584)	(599)	409
Accounts payable and accrued liabilities	5,241	368	3,710
Income taxes	(842)	(59)	76
Deferred revenue	20,651	(124)	(129)
Net cash provided by operating activities	34,052	14,053	25,166
Investing Activities:
Purchases of property and equipment	(9,092)	(6,432)	(8,192)
Cash proceeds from sale of property and equipment			89
Purchases of available-for-sale securities	(81,536)	(73,671)	(24,517)
Sales and maturities of available-for-sale securities	71,951	63,871	2,498
Purchase of in-process research and development (Note 11)	(5,000)
Payments for acquisition, net of cash acquired			(25,859)
Cash received from strategic investments	177	43	513
Net cash used in investing activities	(23,500)	(16,189)	(55,468)
Financing Activities:
Issuance of common stock	2,089	444	494
Repurchase of common stock		(4,702)
Payments for taxes related to net share settlement of equity awards	(4,557)	(2,156)	(388)
Payment of deferred financing costs		(96)
Payment of contingent consideration	(925)		(305)
Net cash used in financing activities	(3,393)	(6,510)	(199)
Effect of exchange rate changes on cash	(25)	193	(100)
Net change in cash and cash equivalents	7,134	(8,453)	(30,601)
Cash, Restricted Cash and Cash Equivalents:
Beginning of year	16,534	24,987	55,588
End of year	23,668	16,534	24,987
Supplemental Information:
Cash paid for income taxes	914	2,114	6,710
Noncash financing and investing activities:
Acquisition of property and equipment on account, net of refundable credits in other current assets	632	$ 109	50
Acquisition of property and equipment in long-term deferred rent	1,200
Acquisition of in process research and development in other long-term liabilities	2,888
Accrual of employee taxes on common stock exercises	$ 130		1,585
Contingent consideration and debt assumed in acquisitions			$ 12,584

Schedule of Valuation and Quali

Schedule of Valuation and Qualifying Accounts	12 Months Ended
	Sep. 30, 2018
Valuation And Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts	Surmodics, Inc. Valuation and Qualifying Accounts (In thousands) Description (1) Balance at Beginning of Period Additions Charged (Credited) to Expenses Deductions From Reserves Balance at End of Period Year Ended September 30, 2016: Allowance for doubtful accounts $ 10 $ 9 $ — (a) $ 19 Year Ended September 30, 2017: Allowance for doubtful accounts $ 19 $ 222 $ 11 (a) $ 230 Year Ended September 30, 2018: Allowance for doubtful accounts $ 230 $ 64 $ 147 (a) $ 147 (1) Uncollectible accounts written off and adjustments to the allowance.

Description

Description	12 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Description	1. Description in vitro Basis of Presentation The consolidated financial statements include all accounts and wholly-owned subsidiaries, and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.”) (“GAAP”). All inter-company transactions have been eliminated.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Select Balance Sheet Information	12 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Select Balance Sheet Information	2. Summary of Significant Accounting Policies and Select Balance Sheet Information Cash, Restricted Cash and Cash Equivalents Cash, restricted cash and cash equivalents consist of financial instruments with maturities of three months or less at the Company’s acquisition date of the security and are stated at cost which approximates fair value and may include money market instruments, certificates of deposit, repurchase agreements and commercial paper instruments. Restricted cash represents cash balances restricted pursuant to the terms of a real estate lease Investments Investments consisted principally of commercial paper and corporate bond securities and are classified as available-for-sale as of September 30, 2018 and 2017. Available-for-sale securities are reported at fair value with unrealized gains and losses, net of tax, excluded from the consolidated statements of operations and reported in the consolidated statements of comprehensive (loss) income as well as a separate component of stockholders’ equity in the consolidated balance sheets, except for other-than-temporary impairments, which are reported as a charge to current earnings. A loss would be recognized when there is an other-than-temporary impairment in the fair value of any individual security classified as available-for-sale, with the associated net unrealized loss reclassified out of accumulated other comprehensive income with a corresponding adjustment to other income (loss). This adjustment would result in a new cost basis for the investment. No such adjustments occurred during the years ended September 30, 2018, 2017 or 2016. Interest earned on debt securities, including amortization of premiums and accretion of discounts, is included in other income (loss). Realized gains and losses from the sales of available-for-sale debt securities, which are included in other income (loss), are determined using the specific identification method. The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities as of September 30, 2018 and 2017 (in thousands): September 30, 2018 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper and corporate bonds $ 41,403 $ — $ (51 ) $ 41,352 Total $ 41,403 $ — $ (51 ) $ 41,352 September 30, 2017 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper and corporate bonds $ 31,817 $ — $ (15 ) $ 31,802 Total $ 31,817 $ — $ (15 ) $ 31,802 There were no held-to-maturity debt securities as of September 30, 2018 or 2017 and no realized gains or losses on sales of available-for-sale securities for the years ended September 30, 2018, 2017 or 2016. Inventories Inventories are principally stated at the lower of cost or market using the specific identification method and include direct labor, materials and overhead. Inventories consisted of the following components as of September 30 (in thousands): 2018 2017 Raw materials $ 1,890 $ 1,603 Work in-process 780 659 Finished products 1,346 1,254 Total $ 4,016 $ 3,516 Property and Equipment Property and equipment are stated at cost, less any impairment, and are depreciated using the straight-line method over the estimated useful lives of the assets. The Company recorded depreciation expense of $3.7 million, $3.0 million and $2.3 million for the years ended September 30, 2018, 2017 and 2016, respectively. The September 30, 2018 and 2017 balances in construction-in-progress include the cost of enhancing the capabilities of the Company’s Ballinasloe, Ireland and Eden Prairie, Minnesota facilities. As assets are placed in service, construction-in-progress is transferred to the specific property and equipment categories and depreciated over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the term of the lease or the estimated useful life of the asset. Expenditures for maintenance and repairs and minor renewals and betterments that do not extend or improve the life of the respective assets are expensed as incurred. Property and equipment consisted of the following components as of September 30 (in thousands): Useful Life 2018 2017 (In years) Land N/A $ 4,420 $ 4,420 Laboratory fixtures and equipment 3 to 10 22,024 19,491 Buildings and improvements 3 to 20 21,717 21,924 Leasehold improvements 10 4,836 — Office furniture and equipment 3 to 10 5,824 4,541 Construction-in-progress 4,834 2,493 Less accumulated depreciation (33,512 ) (29,927 ) Property and equipment, net $ 30,143 $ 22,942 Other Assets Other assets consist principally of the following as of September 30 (in thousands): 2018 2017 ViaCyte, Inc. $ 479 $ 479 Other noncurrent assets 967 418 Other assets, net $ 1,446 $ 897 The Company has invested a total of $5.3 million in ViaCyte, Inc. (“ViaCyte”), a privately-held California-based biotechnology firm that is developing a unique treatment for diabetes using coated islet cells, the cells that produce insulin in the human body. In fiscal 2006, the Company determined that its investment in ViaCyte was impaired and that the impairment was other-than-temporary. Accordingly, the Company recorded an impairment loss of $4.7 million. In the second quarter of fiscal 2013, the Company recorded an additional other-than-temporary impairment loss on this investment totaling $0.1 million based on a financing round and market valuations. The balance of the investment of $0.5 million, which is accounted for under the cost method, represents less than a 1% ownership interest. The Company does not exert significant influence over ViaCyte’s operating or financial activities. The total carrying value of cost method investments is reviewed quarterly for changes in circumstances or the occurrence of events that suggest the Company’s investment may not be recoverable. The carrying value of cost method investments is not adjusted if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment. In the years ended September 30, 2018, 2017 and 2016, the Company recognized revenue of less than $0.1 million in each period from activity with companies in which it had a strategic investment. Intangible Assets Intangible assets consist principally of acquired patents and technology, customer lists and relationships, licenses and trademarks. The Company recorded amortization expense of $2.7 million, $2.6 million and $2.4 million for the years ended September 30, 2018, 2017 and 2016, respectively. Intangible assets consisted of the following as of September 30 (in thousands): 2018 Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 18,086 $ (9,377 ) $ 8,709 Developed technology 11.5 9,656 (2,361 ) 7,295 Non-compete 5.0 230 (150 ) 80 Patents and other 16.5 2,321 (1,569 ) 752 Subtotal 30,293 (13,457 ) 16,836 Unamortized intangible assets: In-process research and development 267 — 267 Trademarks and trade names 580 — 580 Total $ 31,140 $ (13,457 ) $ 17,683 2017 Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 18,293 $ (7,834 ) $ 10,459 Developed technology 11.7 9,297 (1,478 ) 7,819 Non-compete 5.0 230 (103 ) 127 Patents and other 16.5 2,321 (1,423 ) 898 Subtotal 30,141 (10,838 ) 19,303 Unamortized intangible assets: In-process research and development 679 — 679 Trademarks and trade names 580 — 580 Total $ 31,400 $ (10,838 ) $ 20,562 Based on the intangible assets in service, excluding any possible future amortization associated with acquired (in thousands): 2019 $ 2,690 2020 2,514 2021 2,375 2022 2,336 2023 1,737 Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, completion or abandonment of IPR&D intangible assets, changes in amortization periods, foreign currency exchange rates or other factors. The Company defines IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and is capitalized as an indefinite-lived intangible asset until completion or abandonment of the IPR&D project. Upon completion of the development project (generally when regulatory approval to market the product is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects were abandoned, the related IPR&D assets would be written off. The Company assesses indefinite-lived assets for impairment annually in the fourth quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Similar to the goodwill impairment test, the indefinite-lived assets impairment test requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company performed its annual impairment analysis as of August 31, 2018 and did not record any impairment charges in fiscal 2018 as there were no indicators of impairment associated with the indefinite-lived intangible assets. As a result of the August 31, 2017 impairment analysis, impairment losses on indefinite-lived intangible assets of $0.3 million and $0.1 million were recorded selling, general and administrative expenses, respectively, in the consolidated statements of operations for . No other impairment losses were identified during the annual impairment analyses in fiscal 2018 or 2017. Goodwill Goodwill represents the excess of the purchase price of an acquired business over the fair value assigned to the assets purchased and liabilities assumed. Goodwill is not amortized but is subject, at a minimum, to annual tests for impairment in accordance with accounting guidance for goodwill. The carrying amount of goodwill is evaluated annually, and between annual evaluations if events occur or circumstances change indicating that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company’s reporting units are the In Vitro Diagnostics and Medical Device operating segments. Inherent in the determination of fair value of the reporting units are certain estimates and judgments, including the interpretation of current economic indicators and market valuations as well as the Company’s strategic plans with regard to its operations. The Company performed its annual assessment of goodwill for impairment as of August 31, 2018 and no goodwill impairment charges were recorded as there were no indicators of impairment associated with either of the reporting units. The impairment assessment is reliant on forecasted cash flows, as well as the selected discount rate when a quantitative assessment is necessary, which are inherently subjective and require significant management estimates. Differences in the reporting units’ actual future operating results as compared with these forecasted estimates could materially affect the estimation of the fair value of the reporting units. The Company did not record any goodwill impairment charges in the years ended September 30, 2018, 2017 or 2016. Goodwill as of September 30, 2018 and 2017 totaled $27.0 million and $27.3 million, respectively. Goodwill related to the In Vitro Diagnostics reporting unit represents the gross value from the acquisition of BioFX Laboratories, Inc. in 2007. As part of the acquisition of Creagh Medical, Ltd. and NorMedix, Inc. in fiscal 2016 (Note 4), the Medical Device reporting segment added $17.9 million of goodwill during fiscal 2016, $13.4 million of which is denominated in Euros and subject to revaluation due to fluctuations in exchange rates. The change in the carrying amount of goodwill by segment for the years ended September 30, 2018 and 2017 was as follows (in thousands) (Dollars in thousands) In Vitro Diagnostics Medical Device Total Balance as of September 30, 2016 $ 8,010 $ 18,545 $ 26,555 Foreign currency translation adjustment — 727 727 Balance as of September 30, 2017 8,010 19,272 27,282 Foreign currency translation adjustment — (250 ) (250 ) Balance as of September 30, 2018 $ 8,010 $ 19,022 $ 27,032 Valuation of Long-Lived Assets Accounting guidance requires the Company to evaluate periodically whether events and circumstances have occurred that may affect the estimated useful life or the recoverability of the remaining balance of long-lived assets, such as property and equipment and intangibles with finite lives. If such events or circumstances were to indicate that the carrying amount of these assets may not be recoverable, the Company would estimate the future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected future cash flows (undiscounted and without interest charges) were less than the carrying amount of the assets, the Company would recognize an impairment charge to reduce such assets to their fair value. In fiscal 2018, 2017 and 2016, there were no impairment charges relating to the Company’s long-lived assets as there were no events or circumstances that occurred that affected the recoverability of such assets. Accrued Liabilities Other accrued liabilities consisted of the following as of September 30 (in thousands): 2018 2017 Accrued professional fees $ 311 $ 501 Accrued clinical study expense 2,839 411 Accrued purchases 533 596 Customer claim 1,000 — Construction in progress 1,199 — Deferred rent 121 18 Other 262 247 Total $ 6,265 $ 1,773 Revenue Recognition The Company recognizes revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) shipment has occurred or delivery has occurred if the terms specify destination; (3) the sales price is fixed or determinable; and (4) collectability is reasonably assured. When there are additional performance requirements, revenue is recognized when all such requirements have been satisfied. Under revenue arrangements with multiple deliverables, the Company recognizes each separable deliverable as it is earned. The Company derives its revenue from three primary sources: (1) royalties and license fees from licensing our proprietary surface modification coating, and medical device technologies to customers; (2) product revenue from the sale of reagent chemicals to licensees, the sale of stabilization products, antigens, substrates and surface coatings to the diagnostic and biomedical research markets as well as the sale of medical devices (such as balloons and catheters) and related products to OEM suppliers and distributors; and (3) research and commercial development fees generated on customer projects. Taxes collected from customers and remitted to governmental authorities are excluded from revenue and amounted to $0.1 million for each of the years ended September 30, 2018, 2017 and 2016. Royalties and license fees . The Company licenses technology to third parties and collects royalties. Sales-based royalty revenue is generated when a customer sells products incorporating the Company’s licensed technologies. Royalty revenue is recognized as licensees report it to the Company, and payment is typically submitted concurrently with the report. For stand-alone license agreements, up-front license fees are recognized based on the terms of the related licensing agreement, either over the term of the agreement or at the point in time when the earnings process is complete. Minimum royalty fees are recognized in the period earned. Revenue related to a performance milestone is recognized upon the achievement of the milestone, as defined in the respective agreements and provided the following conditions have been met: • The milestone payment is non-refundable; • The milestone involved a significant degree of risk, and was not reasonably assured at the inception of the arrangement; • Accomplishment of the milestone involved substantial effort; • The amount of the milestone payment is commensurate with the related effort and risk; and • A reasonable amount of time passed between the initial license payment and the first and subsequent milestone payments. If these conditions have not been met, the milestone payment is deferred and recognized over the term of the agreement. Product sales. Product sales to third parties consist of OEM and distributor sales and are recognized at the time of shipment. The Company’s sales terms provide no right of return outside of the standard warranty policy. Payment terms are generally set at 30-45 days. Research and development. The Company performs third-party research and development activities, which are typically provided on a time and materials basis. Generally, revenue for research and development is recorded as performance progresses under the applicable contract, which corresponds with the period the related costs are incurred. Arrangements with multiple deliverables. Revenue arrangements with multiple deliverables require the Company to: (i) disclose whether multiple deliverables exist, how the deliverables in an arrangement should be separated, and how the consideration should be allocated; (ii) allocate revenue in an arrangement using estimated selling prices (“ESP”) of deliverables if a vendor does not have vendor-specific objective evidence of selling price (“VSOE”) or third-party evidence of selling price (“TPE”); and (iii) allocate revenue using the relative selling price method. The Company accounts for revenue using a multiple attribution model in which consideration allocated to research and development activities is recognized as performed, and milestone payments are recognized when the milestone events are achieved, when such activities and milestones are deemed substantive. Accordingly, in situations where a unit of accounting includes both a license and research and development activities, and when a license does not have stand-alone value, the Company applies a multiple attribution model in which consideration allocated to the license is recognized ratably, consideration allocated to research and development activities is recognized as performed and milestone payments are recognized when the milestone events are achieved, when such activities and milestones are deemed substantive. The Company enters into license and development arrangements that may consist of multiple deliverables which could include license(s) to Surmodics’ technology, research, development and clinical activities, and product sales based on the needs of its customers. For example, a customer may enter into an arrangement to obtain a license to Surmodics’ intellectual property which may also include research, development and clinical activities, as well as supply of products manufactured by Surmodics. For these services provided, Surmodics could receive upfront license fees upon signing of an agreement and granting the license, milestone payments contingent upon advancement of the product through development and clinical stages to successful commercialization, per-unit payments for supply of product, and royalty payments based on customer sales of product incorporating Surmodics’ technology. The Company’s license and development arrangements generally do not have refund provisions if the customer cancels or terminates the agreement. Typically all payments made are non-refundable. The Company is required to evaluate each deliverable in a multiple element arrangement for separability. The Company is then required to allocate revenue to each separate deliverable using a hierarchy of VSOE, TPE, or ESP. In many instances, the Company is not able to establish VSOE for all deliverables in an arrangement with multiple elements. This may be a result of the Company infrequently selling each element separately or having a limited history with multiple element arrangements. When VSOE cannot be established, the Company attempts to establish a selling price of each element based on TPE. TPE is determined based on competitor prices for similar deliverables when sold separately. When the Company is unable to establish a selling price using VSOE or TPE, the Company uses ESP in its allocation of arrangement consideration. The objective of ESP is to determine the price at which the Company would transact a sale if the product or service were sold on a stand-alone basis. ESP is generally used for highly customized offerings. The Company determines ESP for undelivered elements by considering multiple factors including, but not limited to, market conditions, competitive landscape and past pricing arrangements with similar features. The determination of ESP is made through consultation with the Company’s management, taking into consideration the marketing strategies for each business unit. Deferred Revenue Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated balance sheets, with deferred revenue to be recognized beyond one year being classified as non-current deferred revenue. The Company had deferred revenue of $20.9 million and $0.3 million as of September 30, 2018 and 2017, respectively recorded in current and long-term deferred revenue on the consolidated balance sheets. Concentrations The Company has licenses and supply agreements with a diverse base of customers and certain customers have multiple products using the Company’s technology. Medtronic plc (“Medtronic”) is the Company’s largest customer at approximately 16%, 18% and 25% of total consolidated revenue for the years ended September 30, 2018, 2017 and 2016, respectively. Medtronic has several separately-licensed products that generate royalty revenue for Surmodics, none of which represented more than 4% of Surmodics’ total revenue. As discussed in Note 3, the Company entered into an agreement with Abbott Vascular, Inc. (“Abbott”) during the year ended September 30, 2018. As a result of revenue recognized under this and other agreements, revenue from Abbott and its affiliates accounted for 11% of consolidated revenue in the year ended September 30, 2018. No other individual customer constitutes more than 10% of the Company’s total revenue. The loss of Medtronic, Abbott or any of our largest customers, or reductions in business from them, could have a material adverse effect on the Company’s business, financial condition, results of operations, and cash flows from operations. The Company’s licensing agreements with many of its customers, including most of its significant customers, cover many licensed products that each separately generates royalty revenue. This structure reduces the potential risk to the Company’s operations that may result from reduced sales (or the termination of a license) of a single product for any specific customer. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy and that credit risk related to accounts receivable is limited due to a large customer base. Income Taxes The Company accounts for income taxes under the asset and liability method prescribed in accounting guidance. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in this assessment. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in earnings in the period that includes the enactment date of such change. Research and Development Research and development (“R&D”) costs are expensed as incurred. Some R&D costs are related to customer contracts, and the related revenue is recognized as described in “Revenue Recognition” above. Costs associated with customer-related R&D include specific project direct labor and material expenses as well as an allocation of overhead costs based on direct labor dollars. Clinical trial costs. The Company sponsors clinical trials intended to obtain the necessary clinical data required to obtain approval from various regulatory agencies to market medical devices developed by the Company. Costs associated with clinical trials are included within R&D expense and include trial design and management expenses, clinical site reimbursements and third party fees. The Company’s clinical trials are administered by third-party clinical research organizations (“CROs”). These CROs generally bill monthly for certain services performed as well as upon achievement of certain milestones. The Company monitors patient enrollment, the progress of clinical studies and related activities through internal reviews of data reported to the Company by the CROs and correspondence with the CROs. The Company periodically evaluates its estimates to determine if adjustments are necessary or appropriate based on information it receives. Government funding . The Company is eligible to receive reimbursement for certain qualifying R&D expenditures under a grant from the Industrial Development Agency of Ireland (“IDA”). Reimbursements are recognized as a reduction of R&D expense when there is reasonable assurance that the funding will be received and conditions associated with the funding are met. The Company recorded reimbursements from IDA grants of $0.8 million during each of the years ended September 30, 2018 and 2017 as a reduction of R&D expense. No reimbursements were recorded during fiscal 2016. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates. Income Per Share Data Basic (loss) income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted income per common share is computed by dividing income by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options and non-vested stock relating to restricted stock awards, restricted stock units and performance shares. However, these items have been excluded from the calculation of diluted net loss per share as their effect is antidilutive for the year ended September 30, 2018, as a result of the net loss incurred for that period. Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the year ended September 30, 2018. The following table sets forth the denominator for the computation of basic and diluted income per share for each of the years ended September 30 (in thousands): 2018 2017 2016 Net income from continuing operations available to common shareholders $ (4,457 ) $ 3,926 $ 9,985 Basic weighted average shares outstanding 13,157 13,153 12,998 Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units and performance shares — 236 221 Diluted weighted average shares outstanding 13,157 13,389 13,219 The calculation of weighted average diluted shares outstanding excludes outstanding common stock options associated with the right to purchase 0.2 million and 0.7 million shares for fiscal 2017 and 2016, respectively, as their inclusion would have had an antidilutive effect on diluted income per share for those fiscal years. Currency Translation The Company’s reporting currency is the U.S. Dollar. Assets and liabilities of non-U.S. dollar functional currency subsidiaries are translated into U.S. dollars at the period-end exchange rates, and revenue and expenses are translated at the average quarterly exchange rates during the period. The net effect of these translation adjustments on the consolidated financial statements is recorded as a foreign currency translation adjustment, a component of accumulated other comprehensive income New Accounting Pronouncements Accounting Standards to be Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) This accounting standard will be adopted by the Company beginning in the first quarter of fiscal year 2019 (October 1, 2018) using the modified retrospective approach and the impact will be material to the consolidated financial statements due to an anticipated one-quarter acceleration of minimum license fees and sales-based royalty revenue earned under its hydrophilic license agreements. These changes will result in an increase of approximately $5.9 million to retained earnings, including establishment of contract assets on the consolidated balance sheets of $7.6 million and a deferred tax liability of $1.7 million upon adoption. In February 2016, the FASB issued ASU 2016-02, Leases (ASC Topic 842) While the Company is evaluating the impact of the lease guidance on its consolidated financial statements, the Company anticipates that the impact will be material due to the right-of-use assets and lease liabilities related to existing operating leases that will be recorded on the Company’s consolidated balance sheets upon adoption of the standard In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses (ASC Topic 326), Measurement of Credit Losses on Financial Statements Accounting Standards Implemented In January 2017, the FASB issued ASU No. 2017-01, Clarifying the Definition of a Business Business Combinations No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s consolidated financial statements.

Collaborative Arrangement

Collaborative Arrangement	12 Months Ended
	Sep. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborative Arrangement	3. Collaborative Arrangement On February 26, 2018, the Company entered into an agreement with Abbott whereby Abbott will have exclusive worldwide commercialization rights for Surmodics' SurVeil® drug-coated balloon to treat the superficial femoral artery, which is currently being evaluated in a U.S. pivotal clinical trial. Separately, Abbott also received options to negotiate agreements for Surmodics' below-the-knee and arteriovenous (AV) fistula DCB products, which are currently in pre-clinical development. Surmodics is responsible for conducting all necessary clinical trials and other activities required to achieve U.S. and European Union regulatory clearances for the SurVeil SurVeil The Company has received a $25 million upfront fee and may receive up to $67 million of additional payments upon achievement of various clinical and regulatory milestones. Revenue from the upfront fee and clinical and regulatory milestone payments, if any are achieved, are recognized within royalties and license fees in the consolidated statements of operations as the clinical and regulatory activities are performed on a proportional performance basis based on actual costs incurred relative to the expected total cost of the underlying activities, most notably the completion of the TRANSCEND clinical trial. A significant component of the cost of this trial is the cost of our outsourced clinical trial clinical research organization (“CRO”) consultants, which are estimated based on executed statements of work, project budgets, and patient enrollment timing, among other things. A significant change to the Company’s estimate of the costs to complete the TRANSCEND clinical trial could have a material effect on the Company’s results of operations. The total expected cost of the trial is a significant management estimate and is reviewed and assessed each reporting period. For the year ended September 30, 2018, the Company recognized revenue totaling $4.4 million from the upfront fee from the Abbott arrangement. The remainder of the $25 million upfront fee is included in deferred revenue in current and long-term deferred revenue as of September 30, 2018, totaling $9.6 million and $11.1 million, respectively. Upon receipt of regulatory approval for the SurVeil

Business Combinations

Business Combinations	12 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Business Combinations	4. Business Combinations For all business combinations, the Company records all assets and liabilities of the acquired business, including goodwill and other identified intangible assets, at their respective fair values as of the acquisition date. Contingent consideration, if any, is recognized at its fair value on the acquisition date and changes in fair value are recognized in earnings until settlement. Acquisition-related transaction costs are expensed as incurred. Creagh Medical Ltd. On November 20, 2015, the Company acquired 100% of the outstanding common shares and voting shares of Creagh Medical located in Ballinasloe, Ireland. The results of Creagh Medical’s operations have been included in the Company’s consolidated financial statements as of the Creagh Medical acquisition date. The acquisition was financed with cash on hand and contingent seller financing. The Company acquired Creagh Medical for up to €30 million (approximately $32 million as of the acquisition date), including an upfront payment of €18 million (approximately $19.3 million as of the acquisition date), and up to €12 million (approximately $12.8 million as of the acquisition date) based on achievement of revenue and value-creating operational milestones through September 30, 2018. Based on milestones achieved during the contingency period, a payment totaling €9.6 million is expected to be made by December 31, 2018, which is equivalent to approximately $11.1 million since the acquisition date The Company realized $3.3 million of revenue and a loss of $2.7 million from Creagh Medical’s operations for the period from the acquisition date through September 30, 2016. Creagh Medical designs and manufactures percutaneous transluminal angioplasty (“PTA”) balloon catheters. The purchase price of Creagh Medical consisted of the following (in thousands) Cash paid $ 18,449 Debt assumed 761 Contingent consideration 9,064 Total purchase price 28,274 Less cash and cash equivalents acquired (251 ) Total purchase price, net of cash acquired $ 28,023 The purchase accounting allocation of assets acquired and liabilities assumed was finalized during the fourth quarter of fiscal 2016. During the measurement period, which ended September 30, 2016, certain insignificant adjustments were made from amounts previously reported to finalize Creagh’s preliminary fair value estimates related primarily to other current assets, intangible assets, goodwill, certain property value, contingent liabilities and the related deferred tax impacts. The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the Creagh Medical acquisition: Fair Value (Dollars in thousands) Estimated Useful Life (In years) Current assets $ 896 N/A Property and equipment 634 1.0-10.0 Trade name 75 N/A Developed technology 1,787 7.0 In-process research and development 942 N/A Customer relationships 11,119 7.0-10.0 Other noncurrent assets 81 N/A Current liabilities (942 ) N/A Deferred tax liabilities (9 ) N/A Net assets acquired 14,583 Goodwill 13,440 N/A Total purchase price, net of cash acquired $ 28,023 The Creagh Medical goodwill, which is a result of acquiring and retaining the Creagh Medical existing workforce and expected synergies from integrating their business into the Company’s Medical Device segment, is not deductible for tax purposes. NorMedix, Inc. On January 8, 2016, the Company acquired 100% of the shares of NorMedix, a privately owned design and development company focused on ultra-thin-walled, minimally invasive catheter technologies based in Plymouth, Minnesota. This acquisition strengthened the Company’s vascular device expertise and R&D capabilities and was financed with cash on hand and contingent seller financing. The Company acquired NorMedix for up to $14.0 million, including an upfront payment of $7.0 million, and up to $7.0 million based on achievement of revenue and value-creating operational milestones through September 30, 2019. During the year ended September 30, 2018, a total of $0.9 million was paid to the sellers for revenue and strategic milestones achieved. In November 2018, the share purchase agreement was amended to modify or clarify the definition of the remaining, unearned revenue and strategic milestones and to fix the payment date for any milestones achieved during the remaining contingency period. Additional contingent consideration earned under the amended NorMedix share purchase agreement, if any, will be payable in November 2019. Total transaction, integration and other costs associated with the NorMedix acquisition aggregated $0.3 million for the year ended September 30, 2016. NorMedix’s operating results have been included in the Medical Device segment since the acquisition date. The Company realized $0.9 million of revenue and a loss of $0.4 million from NorMedix’s operations for the period from the acquisition date through The purchase price of NorMedix consisted of the following (in thousands) Cash paid $ 6,905 Contingent consideration 3,520 Total purchase price 10,425 Less cash and cash equivalents acquired (17 ) Total purchase price, net of cash acquired $ 10,408 The purchase accounting allocation of assets acquired and liabilities assumed was finalized during the fourth quarter of fiscal 2016. During the measurement period, which ended September 30, 2016, certain insignificant adjustments were made from amounts previously reported to finalize NorMedix’s preliminary fair value estimates related primarily to working capital, intangible assets, goodwill, certain property value, contingent liabilities and the related deferred tax impacts. The following table summarizes the allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the NorMedix acquisition: Fair Value (Dollars in thousands) Estimated Useful Life (In years) Net current assets $ 113 N/A Property and equipment 60 7.0 Developed technology 6,850 10.0-14.0 Customer relationships 900 4.0 Deferred tax asset 690 N/A Other noncurrent asset 13 N/A Accounts payable (187 ) N/A Deferred tax liabilities (2,483 ) N/A Net assets acquired 5,956 Goodwill 4,452 N/A Total purchase price, net of cash acquired $ 10,408 The NorMedix goodwill, which is a result of acquiring and retaining the NorMedix existing workforce and expected synergies from integrating their business into the Medical Device segment, is not deductible for tax purposes. Unaudited Pro Forma Results The following unaudited pro forma financial information presents the combined results of operation of the Company as if the acquisitions of Creagh Medical and NorMedix had occurred as of October 1, 2014, the beginning of fiscal 2015. The fiscal 2016 unaudited pro forma financial information includes adjustments for additional amortization expense on identifiable intangible assets of $2.8 million and contingent consideration accretion expense of $1.8 million, and to eliminate non-recurring, transactional professional fees of $3.2 million, and the related tax effect impact of $0.2 million. The tax impact of the adjustments reflects no tax benefit from either the contingent consideration expense or a significant portion of the transaction related costs in fiscal 2016 as they are not deductible for tax purposes. Further, Creagh Medical amortization expense does not reflect an Irish tax benefit as the Company acquired a net operating loss carryforward as of the acquisition date that was offset in the aggregate by deferred tax liabilities and a valuation allowance. Therefore, the amortization of Creagh Medical intangible assets results in an increase in deferred tax liabilities with a corresponding increase to a deferred tax valuation allowance. NorMedix amortization expense reflects a tax benefit based on the Company’s incremental U.S. tax rate. The unaudited pro forma financial information is not necessarily indicative of what the Company’s consolidated results of operations actually would have been had the acquisition occurred at the beginning of fiscal 2015. Additionally, the unaudited pro forma financial information does not attempt to project the future operating results of the combined company. Years Ended September 30, 2016 (In thousands, except per share data) (Unaudited) Revenue $ 72,416 Income from continuing operations 10,590 Loss from discontinued operations, net of income taxes — Net income $ 12,315 Per share amounts: Basic net income per share $ 0.95 Diluted net income per share $ 0.93

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements The accounting guidance on fair value measurements defines fair value, establishes a framework for measuring fair value under U.S. GAAP, and expands disclosures about fair value measurements. The guidance is applicable for all financial assets and financial liabilities and for all nonfinancial assets and nonfinancial liabilities recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. Fair Value Hierarchy Accounting guidance on fair value measurements requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities. The Company did not have any Level 1 assets as of September 30, 2018 or 2017. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. The Company’s Level 2 assets as of September 30, 2018 and 2017 consisted of money market funds, commercial paper instruments and corporate bond securities. Fair market values for these assets are based on quoted vendor prices and broker pricing where all significant inputs are observable. To ensure the accuracy of quoted vendor prices and broker pricing, the Company performs regular reviews of investment returns to industry benchmarks and sample tests of individual securities to validate quoted vendor prices with other available market data. Level 3 — Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation. Included in Level 3 liabilities as of September 30, 2018 is a $14.5 million contingent consideration liability, of which $3.4 million is noncurrent. Included in Level 3 liabilities as of September 30, 2017 is a $14.9 million contingent consideration liability, of which $13.1 million is noncurrent. The current contingent consideration liability represents the liability for revenue and strategic milestones achieved during a contingency period which ended September 30, 2018. The non-current contingent consideration liabilities are subject to achievement of revenue and value-creating milestones in the period ending September 30, 2019. There were no Level 3 assets as of September 30, 2018 or 2017. In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company did not significantly change its valuation techniques from prior periods. The carrying value of cash, accounts receivable, accounts payable and accrued liabilities approximates fair value as of September 30, 2018 and 2017 due to the short maturity nature of these instruments. Assets and Liabilities Measured at Fair Value on a Recurring Basis In instances where the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2018 (in thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value as of September 30, 2018 Assets Cash equivalents $ — $ 13,999 $ — $ 13,999 Available-for-sale securities — 41,352 $ 41,352 Total assets $ — $ 55,351 $ — $ 55,351 Liabilities Contingent consideration $ — $ — $ (14,466 ) $ (14,466 ) Total liabilities $ — $ — $ (14,466 ) $ (14,466 ) The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2017 (in thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value as of September 30, 2017 Assets Cash equivalents $ — $ 6,639 $ — $ 6,639 Available-for-sale securities — 31,802 $ 31,802 Total assets $ — $ 38,441 $ — $ 38,441 Liabilities Contingent consideration $ — $ — $ (14,864 ) $ (14,864 ) Total liabilities $ — $ — $ (14,864 ) $ (14,864 ) The following table summarizes the changes in the contingent consideration liability for the years ended September 30, 2018 and 2017: (Dollars in thousands) Contingent consideration liability at September 30, 2016 $ 14,517 Additions — Fair value adjustments (2,350 ) Settlements — Interest accretion 2,223 Foreign currency translation 474 Contingent consideration liability at September 30, 2017 14,864 Additions — Fair value adjustments 288 Settlements (925 ) Interest accretion 387 Foreign currency translation (148 ) Contingent consideration liability at September 30, 2018 $ 14,466 There were no transfers of assets or liabilities to or from amounts measured using Level 3 fair value measurements during fiscal 2018 or 2017. Valuation Techniques The valuation techniques used to measure the fair value of assets are as follows: Cash equivalents — These assets are classified as Level 2 and are carried at historical cost which is a reasonable estimate of fair value because of the relatively short time between origination of the instrument and its expected realization. Available-for-sale securities — These assets are classified as Level 2 and include commercial paper instruments and corporate bonds. These securities are valued based on quoted vendor prices in active markets underlying the securities. Contingent consideration — The contingent consideration liabilities were determined based on discounted cash flow analyses that included revenue estimates, probability of strategic milestone achievement and a discount rate, which are considered significant unobservable inputs as of the acquisition dates and September 30, 2018 and 2017. The contingency period for the Creagh Medical contingent consideration obligation ended September 30, 2018. Based on the milestones achieved during the contingency period, the Company will pay Creagh Medical shareholders approximately €9.6 million by December 31, 2018. This obligation was discounted using the Company’s annualized cost of debt for the three-month period between September 30, 2018 and the expected settlement date, or 2.3%, and is included in current contingent consideration on the consolidated balance sheet as of September 30, 2018 at the then-effective foreign currency exchange rate. In November 2018, the NorMedix share purchase agreement was amended to modify or clarify the definition of the remaining, unearned revenue and strategic milestones and to fix the payment date for any milestones achieved during the remaining contingency period. Probability of completion for the redefined milestones is reflected in the estimated fair value of the NorMedix contingent consideration obligation as of September 30, 2018. For the revenue-based milestones, the Company discounted forecasted revenue by To the extent that actual results differ from these estimates, the fair value of the contingent consideration liabilities could change significantly. (approximately $11.0 million September 30, 2018) Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis The Company’s investments in non-marketable securities of private companies are accounted for using the cost method as the Company does not exert significant influence over the investees’ operating or financial activities. These investments are measured at fair value on a non-recurring basis when they are deemed to be other-than-temporarily impaired. In determining whether a decline in value of non-marketable equity investments in private companies has occurred and is other-than-temporary, an assessment is made by considering available evidence, including the general market conditions in the investee’s industry, the investee’s product development status and subsequent rounds of financing and the related valuation and/or the Company’s participation in such financings. The Company also assesses the investee’s ability to meet business milestones and the financial condition and near-term prospects of the individual investee, including the rate at which the investee is using its cash and the investee’s need for possible additional funding at a potentially lower valuation. The valuation methodology for determining the decline in value of non-marketable equity securities is based on inputs that require management judgment and are Level 3 inputs.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Stockholders' Equity	6. Stockholders’ Equity Repurchase of Common Stock Shares are repurchased from time to time to support the Company’s stock-based compensation programs and to return capital to stockholders. The Company accounts for repurchases of common stock using the par value method. On November 6, 2015 and November 5, 2014, the Company’s Board of Directors authorized the repurchase of up to $20.0 million and $30.0 million, respectively, of the Company’s outstanding common stock in open-market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, tender offers or by any combination of such methods. The authorizations have no fixed expiration date. During fiscal 2017, we paid $4.7 million to repurchase 196,190 common shares in open market purchases . As of September 30, 2018, million remained available to the Company for the purchase of its common stock under outstanding authorizations.

Stock-Based Compensation Plans

Stock-Based Compensation Plans	12 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation Plans	7. Stock-Based Compensation Plans The Company has stock-based compensation plans under which it grants stock options, restricted stock awards, performance share awards, restricted stock units and deferred stock units. Accounting guidance requires all share-based payments to be recognized as an expense, based on their fair values, over the requisite service period. The Company also estimates forfeitures of awards granted, which are based on historical experience and reduce the recognized expense. The Company’s stock-based compensation expenses for the years ended September 30 were allocated to the following expense categories (in thousands): 2018 2017 2016 Product costs $ 69 $ 90 $ 22 Research and development 801 510 324 Selling, general and administrative 3,937 2,872 3,498 Total stock-based compensation expense $ 4,807 $ 3,472 $ 3,844 As of September 30, 2018, approximately $5.7 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately 2.1 years. Such costs include $0.6 million based on payout levels associated with performance share awards that are currently anticipated to be fully expensed because the performance conditions are expected to be met above the minimum levels for each award period. Under the amended 2009 Equity Incentive Plan (“2009 Plan”), the Company is authorized to issue up to 2,000,000, plus the number of shares that have not yet been awarded under the 2003 Equity Incentive Plan, or were awarded and subsequently returned to the pool of available shares under the 2003 Equity Incentive Plan pursuant to its terms. As of September 30, 2018, there were 675,587 shares available for future equity awards, including stock options, restricted stock awards, performance share awards, and restricted stock and deferred stock units, under the 2009 Plan. Stock Option Awards The Company uses the Black-Scholes option pricing model to determine the weighted average grant date fair value of stock options. Weighted average per share fair values of stock options granted during fiscal 2018, 2017 and 2016 were $10.91, $7.63 and $6.95, respectively. The assumptions used as inputs in the model for the years ended September 30 were as follows: 2018 2017 2016 Risk-free interest rates 2.18 % 1.74 % 1.89 % Expected life 4.8 years 4.6 years 4.6 years Expected volatility 33 % 34 % 37 % Dividend yield 0 % 0 % 0 % The risk-free interest rate assumption was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award. The expected life of options granted is determined based on the Company’s experience. Expected volatility is based on the Company’s stock price movement over a period approximating the expected term. Based on management’s judgment, dividend rates are expected to be 0.0% for the expected life of the options. Non-qualified stock options are granted at fair market value on the grant date. Non-qualified stock options expire in seven years or upon termination of employment or service as a Board member. With respect to members of the Board, non-qualified stock options generally become exercisable on a pro-rata basis over the one-year period following the date of grant. With respect to employees, non-qualified stock options generally become exercisable with respect to 25% of the shares on each of the first four anniversaries following the grant date. The stock-based compensation table above includes stock option expenses recognized related to these awards, which totaled $1.6 million, $1.3 million and $1.2 million during fiscal 2018, 2017 and 2016, respectively. As of September 30, 2018, the aggregate intrinsic value of the option shares outstanding and option shares exercisable was $34.4 million and $12.4 million, respectively. As of September 30, 2018, the average remaining contractual life of options outstanding and options exercisable was 4.9 years and 3.8 years, respectively. The total pre-tax intrinsic value of options exercised during fiscal 2018, 2017 and 2016 was $12.1 million, $0.1 million and $5.1 million, respectively. The intrinsic value represents the difference between the exercise price and the fair market value of the Company’s common stock on the last day of the respective fiscal year end. The following table summarizes all stock options activity and stock options outstanding and exercisable under the stock option plans during fiscal 2018, 2017 and 2016: Number of Shares Weighted Average Exercise Price Outstanding at September 30, 2015 1,118,008 $ 20.10 Granted 241,582 20.63 Exercised (437,850 ) 15.68 Forfeited and expired (94,415 ) 31.52 Outstanding at September 30, 2016 827,325 21.30 Granted 229,039 24.08 Exercised (6,819 ) 13.89 Forfeited and expired (47,640 ) 30.65 Outstanding at September 30, 2017 1,001,905 21.54 Granted 269,961 34.08 Exercised (450,495 ) 19.46 Forfeited and expired (110,825 ) 30.18 Outstanding at September 30, 2018 710,546 26.28 Exercisable at September 30, 2018 236,302 $ 22.33 Restricted Stock Awards The Company has entered into restricted stock agreements with certain key employees, covering the issuance of common stock (“Restricted Stock”). Under accounting guidance, these shares are considered to be non-vested shares. The Restricted Stock is released to the key employees if they are employed by the Company at the end of the vesting period. Restricted stock awards generally vest at a 33% rate on each of the first three anniversaries following the grant date. Compensation expense is recognized on a straight-line basis over the vesting term based on the fair value of the common shares on the date of grant. The stock-based compensation table above includes Restricted Stock expenses recognized related to these awards, which totaled $1.0 million, $0.5 million and $0.3 million during fiscal 2018, 2017 and 2016, respectively. The following table summarizes all restricted stock awards activity during fiscal 2018, 2017 and 2016: Number of Shares Weighted Average Grant Price Balance at September 30, 2015 27,775 $ 22.12 Granted 20,108 20.14 Vested (12,311 ) 22.19 Forfeited (2,439 ) 21.17 Balance at September 30, 2016 33,133 20.96 Granted 51,559 25.12 Vested (14,497 ) 21.10 Forfeited (2,278 ) 25.12 Balance at September 30, 2017 67,917 23.98 Granted 56,244 34.38 Vested (28,717 ) 23.78 Forfeited (10,020 ) 29.10 Balance at September 30, 2018 85,424 $ 30.30 Performance Share Awards The Company has entered into performance share agreements with certain key employees, covering the issuance of common stock (“Performance Shares”). The Performance Shares vest upon the achievement of all or a portion of certain performance objectives, which must be achieved during the performance period. The Performance Shares are not issued and outstanding until the performance objectives are met. The Organization and Compensation Committee of the Board of Directors (the “Committee”) approves the performance objectives used for executive compensation programs, which objectives were cumulative earnings per share and cumulative revenue for the three-year performance period for fiscal 2014 awards (2014 – 2016), and are cumulative earnings before interest, income taxes, depreciation and amortization (“EBITDA”) for fiscal 2015 awards (2015 – 2017), fiscal 2016 awards (2016-2018) and fiscal 2017 awards (2016-2018). The Committee did not approve Performance Share awards in fiscal 2018. Assuming that the minimum performance level is attained, the number of shares that may actually vest will vary based on performance from 20% (minimum) to 200% (maximum) of the target number of shares. Shares will be issued to participants as soon as practicable following the end of the performance periods, subject to Committee approval and verification of results. The per-unit compensation cost related to the shares to be granted under each performance period is fixed on the grant date, which is the date the performance period begins. Compensation expense is recognized in each period based on management’s best estimate of the achievement level of the specified performance objectives for Performance Shares for each open performance period. In fiscal 2018, the Company recognized expense of $1.5 million related to probable achievement of performance objectives for three-year Performance Shares granted in fiscal 2017 and 2016. In fiscal 2017, the Company recognized expense of $1.2 million related to probable achievement of performance objectives for three-year Performance Shares granted in fiscal 2017, 2016 and 2015. In fiscal 2016, the Company recognized expense of $1.9 million related to probable achievement of performance objectives for three-year Performance Shares granted in fiscal 2016, 2015 and 2014. The stock-based compensation table above includes the Performance Shares expenses. The fair values of the Performance Shares, at target, were $1.2 million and $1.3 million for grants awarded in fiscal 2017 and 2016, respectively. During the year ended September 30, 2018, the resignation of an executive resulted in the forfeiture of 12,217 Performance Shares at their respective original performance targets. The aggregate number of shares that could be awarded to key employees if the minimum, target and maximum performance goals are met, based upon the fair value at the date of grant is as follows: Performance Period Minimum Shares Target Shares Maximum Shares Fiscal 2016 - 2018 11,910 59,548 119,096 Fiscal 2017 - 2019 9,352 46,758 93,516 The Fiscal 2016 – 2018 awards are expected to be finalized in December 2018 at an estimated 76,400 shares based on performance objective results. Based on the Company’s performance through September 30, 2018, it is estimated that approximately 78,226 shares may be earned for the Fiscal 2017 – 2019 performance period. 1999 Employee Stock Purchase Plan Under the amended 1999 Employee Stock Purchase Plan (“Stock Purchase Plan”), the Company is authorized to issue up to 600,000 shares of common stock. All full-time and part-time U.S. employees can choose to have up to 10% of their annual compensation withheld, with a limit of $25,000, to purchase the Company’s common stock at purchase prices defined within the provisions of the Stock Purchase Plan. As of September 30, 2018 and 2017, there were less than $0.1 million of employee contributions in accrued liabilities in the consolidated balance sheets. Stock compensation expense recognized related to the Stock Purchase Plan for fiscal 2018, 2017 and 2016 totaled $0.1 million or less for each year. The stock-based compensation table above includes the Employee Stock Purchase Plan expenses. Restricted Stock and Deferred Stock Units The Company awarded 21,535 and 16,004 restricted stock units (“RSU”) in fiscal 2018 and 2017, respectively, under the 2009 Plan to non-employee directors and certain key employees in foreign jurisdictions with forfeitures of 528 and 495 in fiscal 2018 and 2017, respectively. Directors may elect to receive their annual fees for services to the Board in deferred stock units (“DSUs”). As of September 30, 2018 and 2017, outstanding DSUs totaled 26,991 and 24,441, respectively, with an estimated fair value of $2.0 million and $0.8 million, respectively. These DSUs are fully vested when granted. Stock-based compensation expense related to DSU awards, totaled $0.1 million, $0.1 million and $0.2 million in fiscal 2018, 2017 and 2016, respectively.

Revolving Credit Facility

Revolving Credit Facility	12 Months Ended
	Sep. 30, 2018
Text Block [Abstract]
Revolving Credit Facility	8. Revolving Credit Facility The Company had a revolving credit facility with available principal totaling $30.0 million, which was scheduled to terminate on November 1, 2019. The Company terminated this agreement on March 29, 2018, at which time there was no outstanding balance.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes Income taxes from continuing operations in the accompanying consolidated statements of operations for the years ended September 30 are as follows (in thousands): 2018 2017 2016 Current (benefit) provision: U.S. Federal $ (890 ) $ 2,125 $ 6,550 U.S. State 51 (72 ) 250 International 41 54 (98 ) Total current (benefit) provision (798 ) 2,107 6,702 Deferred (benefit) provision: U.S. Federal (2,006 ) 1,085 169 U.S. State (271 ) (85 ) (43 ) International — — 135 Total deferred (benefit) provision (2,277 ) 1,000 261 Total (benefit) provision $ (3,075 ) $ 3,107 $ 6,963 In December 2017, the Tax Cuts and Jobs Act (“TCJA”) tax legislation was signed into law, which reduced the U.S. Federal statutory tax rate from 35% to 21%, among other changes. As of September 30, 2018, the Company has fully completed its accounting for the tax effects of the enactment of the TCJA. The fiscal 2018 tax provision includes discrete tax expense of $1.6 million from the revaluation of the Company’s net deferred tax assets based on the enacted tax rate of 21%, as compared with the previous rate of 35%. U.S. tax law requires that taxpayers with a fiscal year beginning before and ending after the effective date of a rate change calculate a blended tax rate for the year based on the pro rata number of days in the year before and after such effective date. As a result, for the fiscal year ended September 30, 2018, our U.S. federal statutory income tax rate will be 24.5%. The reconciliation of the difference between amounts calculated at the statutory U.S. federal tax rate of 24.5%, 35% and 35% for fiscal 2018, 2017 and 2016, respectively, and the Company’s effective tax rate from continuing operations is as follows (in thousands) : 2018 2017 2016 Amount at statutory U.S. federal income tax rate $ (1,845 ) $ 2,461 $ 5,932 Change because of the following items: State income taxes, net of federal benefit (724 ) (13 ) 142 Stock-based compensation (2,063 ) 330 (607 ) Valuation allowance change 960 665 (2,500 ) Tax reserve change 158 (52 ) 258 Federal manufacturing deduction — (313 ) (280 ) U.S. Federal and foreign research and development credits (1,710 ) (706 ) (571 ) Gain on strategic investment and corporate subsidiary — — 2,630 Foreign rate differential 371 948 622 Acquisition-related transaction costs — — 768 Contingent consideration expense (gain) 165 (45 ) 522 Unrealized foreign currency exchange (gain) loss on contingent consideration obligation (23 ) 170 — Federal and state rate change 1,582 — — Other 54 (338 ) 47 Income tax (benefit) provision $ (3,075 ) $ 3,107 $ 6,963 The federal research and development tax credit for fiscal 2016 includes the benefit generated for the period from October 1, 2015 to December 31, 2015, prior to the expiration of the benefit in that period. During fiscal 2016, the Company utilized $7.5 million of capital losses generated in prior years by accelerating built-in gains in the Company’s IVD subsidiary. For tax purposes, this resulted in an increase in the Company’s tax basis in the IVD subsidiary and a $2.6 million reduction in both deferred tax assets and the valuation allowance as of September 30, 2016. Excess tax benefits (shortfalls) related to stock based compensation expense are recorded within income tax benefit (expense) in the consolidated statements of operations and totaled $2.0 million, ($0.2) million and $0.6 million for the fiscal years ended September 30, 2018, 2017 and 2016, respectively. The components of deferred income taxes consisted of the following as of September 30 and result from differences in the recognition of transactions for income tax and financial reporting purposes (in thousands): 2018 2017 Depreciable assets $ (1,019 ) $ (3,335 ) Accruals and reserves 1,308 1,123 Stock-based compensation 1,798 3,370 Impaired strategic investments 1,687 2,701 NOL carryforwards 4,637 3,627 U.S. Federal and state R&D credits 1,896 242 Other 538 810 Valuation allowance (4,541 ) (4,511 ) Total deferred tax assets $ 6,304 $ 4,027 As of September 30, 2018 and 2017, the Company recorded deferred tax asset valuation allowances of $4.5 million. The valuation allowances are primarily related to other-than-temporary impairment losses on strategic investments, state R&D credit carryforwards, and net operating loss carryforwards of Creagh Medical. As of September 30, 2018, the Company had federal and state R&D credit carryforwards of $1.9 million that will begin expiring in 2029 and federal and state net operating loss carryforwards of $1.3 million and $0.3 million that will begin expiring in 2033 and 2022, respectively. Ireland net operating loss carryforward assets totaling $3.2 million, much of which was acquired as part of the Creagh Medical acquisition in fiscal 2016, have an unlimited carryforward period. The U.S. federal and Minnesota net operating losses acquired as part of the NorMedix acquisition are subject to the IRC Section 382 limitation rules. The Company has projected that these loss carryforwards will be utilized with over the nine years remaining in the carryforward period. Unrecognized tax benefits are the differences between a tax position taken, or expected to be taken in a tax return, and the benefit recognized for accounting purposes pursuant to accounting guidance. A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, is as follows (in thousands): 2018 2017 2016 Beginning of fiscal year $ 1,481 $ 1,508 $ 1,248 Increases in tax positions for prior years 61 8 77 Decreases in tax positions for prior years — (35 ) (21 ) Increases in tax positions for current year 735 216 365 Settlements with taxing authorities (613 ) — — Lapse of the statute of limitations (105 ) (216 ) (161 ) End of fiscal year $ 1,559 $ 1,481 $ 1,508 The total amount of unrecognized tax benefits excluding interest and penalties that, if recognized, would affect the effective tax rate as of September 30, 2018, 2017 and 2016, respectively, are $1.4 million, $1.2 million and $1.2 million. Currently, the Company does not expect the liability for unrecognized tax benefits to change significantly in the next 12 months and has classified the above balances on the consolidated balance sheets in other long-term liabilities. Interest and penalties related to unrecognized tax benefits are recorded in income tax expense. As of September 30, 2018, 2017 and 2016, a gross balance of $0.4 million, $0.5 million and $0.6 million, respectively, has been accrued related to the unrecognized tax benefits balance for interest and penalties. The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions as well as several non-U.S. jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. The Internal Revenue Service (“IRS”) completed an examination of our fiscal 2016 U.S. federal income tax return in the third quarter of fiscal 2018, with a payment made associated primarily with timing adjustments. U.S. federal income tax returns for years prior to fiscal 2015 are no longer subject to examination by federal tax authorities. For tax returns for state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2007. For tax returns for non-U.S. jurisdictions, the Company is no longer subject to income tax examination for years prior to 2012. Additionally, the Company has been indemnified of liability for any taxes relating to Creagh Medical and NorMedix for periods prior to the respective acquisition dates, pursuant to the terms of the related share purchase agreements. As of September 30, 2018 and 2017, there were no undistributed earnings in foreign subsidiaries.

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Sep. 30, 2018
Compensation And Retirement Disclosure [Abstract]
Defined Contribution Plan	10. Defined Contribution Plan The Company has a 401(k) retirement and savings plan for the benefit of qualifying U.S. employees, and a defined contribution PRSA plan for the benefit of qualifying Ireland employees. For U.S. employees, the Company matches 50% of employee contributions on the first 6% of eligible compensation. For Ireland employees, the Company makes contributions of up to 8% of eligible compensation on employee contributions of up to 6% of eligible compensation. Company contributions totaling $0.7 million, $0.7 million and $0.3 million have been expensed in the years ended September 30, 2018, 2017 and 2016, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Litigation. From time to time, the Company has been, and may become, involved in various legal actions involving its operations, products and technologies, including intellectual property and employment disputes. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages as well as other relief, including injunctions barring the sale of products that are the subject of the lawsuit, which if granted, could require significant expenditures or result in lost revenue. The Company records a liability in the consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. On January 17, 2018, we entered into a settlement agreement fully resolving the previously disclosed litigation involving Merit Medical Systems, Inc. (“Merit”) and NorMedix. In April 2018, a customer notified the Company that it believes it overpaid hydrophilic coating royalties to the Company from January 2009 through December 2017. During the year ended September 30, 2018, the Company recorded $1.0 million in selling, general and administrative expenses related to this claim. These amounts are included in other accrued liabilities on the condensed consolidated balance sheets as of September 30, 2018. InnoRx, Inc. In January 2005, the Company entered into a merger agreement whereby the Company acquired all of the assets of InnoRx, Inc. (“InnoRx”), an early stage company developing drug-delivery devices and therapies for the ophthalmology market. The Company will be required to issue up to approximately 480,059 additional shares of its common stock to the stockholders of InnoRx upon the successful completion of the remaining development and commercial milestones involving InnoRx technology acquired in the transaction. The Company has not recorded any accrual for this contingency as of September 30, 2018 as the milestones have not been achieved and the probability of achievement is remote. InnoCore Technologies BV. In March 2006, the Company entered into a license agreement whereby Surmodics obtained an exclusive license to a drug-delivery coating for licensed products within the vascular field which included peripheral, coronary and neurovascular biodurable stent product. The license requires an annual minimum payment of 200,000 euros (equivalent to $232,000 using a euro to US $ exchange rate of 1.1602 as of September 30, 2018) until the last patent expires which is currently estimated to be September 2027. The total minimum future payments associated with this license are approximately $2.1 million. The license is currently utilized with one of Surmodics’ drug-delivery technology customers. Operating Leases. The Company leases certain facilities under noncancelable operating lease agreements. Rent expense for the years ended September 30, 2018, 2017 and 2016 was $0.5 million, $0.1 million and $0.1 million, respectively. In November 2017, the Company executed a lease for a 36,000 square feet of office and R&D facility in Eden Prairie, Minnesota. Contractual obligations under the lease agreement total $4.0 million over the ten-year lease term, which commenced in May 2018. Year Ended September 30, 2019 $ 443 2020 452 2021 396 2022 391 2023 399 Thereafter 1,933 Total minimum lease payments $ 4,014 Clinical Trials. The Company has engaged CRO consultants to assist with the administration of its ongoing clinical trials. The Company has executed a contract with a CRO for services rendered in connection with the TRANSCEND pivotal clinical trial for the DCB, including pass-through expenses paid by the CRO of up to $20 million in the aggregate. As of September 30, 2018, an estimated $13.2 million remains to be paid on this contract, which may vary depending on actual pass-through expenses incurred to execute the trial. The Company estimates that the total cost of the TRANSCEND clinical trial will be in the range of $32 million to $40 million from inception to completion. In the event the Company were to terminate any trial, it may incur certain financial penalties which would become payable to the CRO for costs to wind down the terminated trial. Asset Acquisition. In May 2018, the Company entered into an asset purchase agreement with Embolitech, LLC (“Embolitech”) to acquire certain intellectual property assets. As part of the Embolitech Transaction, the Company paid the sellers $5.0 million in fiscal 2018. Additionally, the Company is obligated to pay $3.5 million in several installments beginning December 2019 and ending December 2023. These payments may be accelerated upon the occurrence of certain sales and regulatory milestones. An additional $2.0 million payment is contingent upon the achievement of certain regulatory milestones within a contingency period ending in 2033. The present value of the probable payments totaling $7.9 million is recorded as acquired in-process research and development expense on the consolidated statement of operations for the year ended September 30, 2018. As of September 30, 2018, $2.9 million is included in other long-term liabilities related to the guaranteed installment payments on the consolidated balance sheets.

Reportable Segment Information

Reportable Segment Information	12 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Reportable Segment Information	12. Reportable Segment Information The accounting standards for reporting information about operating segments define operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. For financial accounting and reporting purposes, the Company reports its results for the two reportable segments as follows: (1) the Medical Device unit, which designs, develops and manufactures interventional medical devices, primarily for the peripheral vascular market; surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices; as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic test kits and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings. During fiscal 2016, the Company acquired Creagh Medical and NorMedix, which are included in the Medical Device segment. The tables below present segment revenue, operating income from continuing operations and depreciation and amortization, for the years ended September 30, as follows (in thousands): 2018 2017 2016 Revenue: Medical Device $ 60,513 $ 53,983 $ 53,202 In Vitro Diagnostics 20,823 19,129 18,164 Total revenue $ 81,336 $ 73,112 $ 71,366 Operating (loss) income: Medical Device $ (8,478 ) $ 6,902 $ 16,975 In Vitro Diagnostics 8,619 8,293 7,115 Total segment operating income 141 15,195 24,090 Corporate (8,940 ) (8,092 ) (7,231 ) Total operating (loss) income $ (8,799 ) $ 7,103 $ 16,859 Depreciation and amortization: Medical Device $ 5,376 $ 4,453 $ 3,261 In Vitro Diagnostics 394 412 789 Corporate 661 690 823 Total depreciation and amortization $ 6,431 $ 5,555 $ 4,873 The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments. Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available. Major Customers Revenue from customers that equaled or exceeded 10% of total revenue was as follows for the years ended September 30: 2018 2017 2016 Medtronic 16 % 18 % 25 % Abbott 11 % N/A N/A The revenue from the customers listed is derived from two primary sources: licensing and product sales (primarily in the Medical Device segment). Geographic Revenue and Long-lived Assets Geographic revenue was as follows for the years ended September 30: 2018 2017 2016 Domestic 79 % 77 % 79 % Foreign 21 % 23 % 21 % Long-lived assets, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, by country were as follows as of September 30: 2018 2017 U.S. $ 26,652 $ 20,949 Ireland 21,174 22,555

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Sep. 30, 2018
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)	13. Quarterly Financial Data (Unaudited) The following is a summary of the unaudited quarterly results for the years ended September 30, 2018 and 2017 (in thousands, except per share data). First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal 2018 Total revenue $ 17,013 $ 19,058 $ 22,227 $ 23,038 Operating (loss) income (633 ) 525 (6,250 ) (2,441 ) Net (loss) income (1,556 ) 1,534 (2,682 ) (1,753 ) Basic net (loss) income per share (1): (0.12 ) 0.12 (0.20 ) (0.13 ) Diluted net (loss) income per share (1): (0.12 ) 0.11 (0.20 ) (0.13 ) Fiscal 2017 Total revenue $ 17,761 $ 17,503 $ 17,790 $ 20,058 Operating income 3,268 1,677 1,743 415 Net income 2,300 506 720 400 Basic net income per share (1): 0.17 0.04 0.05 0.03 Diluted net income per share (1): 0.17 0.04 0.05 0.03 (1) The sum of the quarterly net (loss) income per share amounts may not equal the annual income per share total because of changes in the weighted average number of shares outstanding that occurred during the year. In the first quarter of fiscal 2018, the Company recorded a $1.2 million charge related to the revaluation of deferred tax assets to reflect the change in the U.S. Federal tax rate from 35% to 21% in conjunction with the Tax Cuts and Jobs Act tax legislation. In the second quarter of fiscal 2018, the Company entered into a collaborative arrangement with Abbott, which resulted in license fee revenue totaling $4.4 million in the final nine months of the fiscal year. In May 2018, the Company acquired certain technology assets from Embolitech resulting in a $7.9 million charge in the third quarter of fiscal 2018. In the fourth quarter of fiscal 2017, the Company recorded a $1.1 million license fee related to a customer’s acquisition and the Company’s sale of related jointly-owned intellectual property to the acquirer

Summary of Significant Accoun_2

Summary of Significant Accounting Policies and Select Balance Sheet Information (Policies)	12 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Cash, Restricted Cash and Cash Equivalents	Cash, Restricted Cash and Cash Equivalents Cash, restricted cash and cash equivalents consist of financial instruments with maturities of three months or less at the Company’s acquisition date of the security and are stated at cost which approximates fair value and may include money market instruments, certificates of deposit, repurchase agreements and commercial paper instruments. Restricted cash represents cash balances restricted pursuant to the terms of a real estate lease
Investments	Investments Investments consisted principally of commercial paper and corporate bond securities and are classified as available-for-sale as of September 30, 2018 and 2017. Available-for-sale securities are reported at fair value with unrealized gains and losses, net of tax, excluded from the consolidated statements of operations and reported in the consolidated statements of comprehensive (loss) income as well as a separate component of stockholders’ equity in the consolidated balance sheets, except for other-than-temporary impairments, which are reported as a charge to current earnings. A loss would be recognized when there is an other-than-temporary impairment in the fair value of any individual security classified as available-for-sale, with the associated net unrealized loss reclassified out of accumulated other comprehensive income with a corresponding adjustment to other income (loss). This adjustment would result in a new cost basis for the investment. No such adjustments occurred during the years ended September 30, 2018, 2017 or 2016. Interest earned on debt securities, including amortization of premiums and accretion of discounts, is included in other income (loss). Realized gains and losses from the sales of available-for-sale debt securities, which are included in other income (loss), are determined using the specific identification method. The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities as of September 30, 2018 and 2017 (in thousands): September 30, 2018 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper and corporate bonds $ 41,403 $ — $ (51 ) $ 41,352 Total $ 41,403 $ — $ (51 ) $ 41,352 September 30, 2017 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper and corporate bonds $ 31,817 $ — $ (15 ) $ 31,802 Total $ 31,817 $ — $ (15 ) $ 31,802 There were no held-to-maturity debt securities as of September 30, 2018 or 2017 and no realized gains or losses on sales of available-for-sale securities for the years ended September 30, 2018, 2017 or 2016.
Inventories	Inventories Inventories are principally stated at the lower of cost or market using the specific identification method and include direct labor, materials and overhead. Inventories consisted of the following components as of September 30 (in thousands): 2018 2017 Raw materials $ 1,890 $ 1,603 Work in-process 780 659 Finished products 1,346 1,254 Total $ 4,016 $ 3,516
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less any impairment, and are depreciated using the straight-line method over the estimated useful lives of the assets. The Company recorded depreciation expense of $3.7 million, $3.0 million and $2.3 million for the years ended September 30, 2018, 2017 and 2016, respectively. The September 30, 2018 and 2017 balances in construction-in-progress include the cost of enhancing the capabilities of the Company’s Ballinasloe, Ireland and Eden Prairie, Minnesota facilities. As assets are placed in service, construction-in-progress is transferred to the specific property and equipment categories and depreciated over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the term of the lease or the estimated useful life of the asset. Expenditures for maintenance and repairs and minor renewals and betterments that do not extend or improve the life of the respective assets are expensed as incurred. Property and equipment consisted of the following components as of September 30 (in thousands): Useful Life 2018 2017 (In years) Land N/A $ 4,420 $ 4,420 Laboratory fixtures and equipment 3 to 10 22,024 19,491 Buildings and improvements 3 to 20 21,717 21,924 Leasehold improvements 10 4,836 — Office furniture and equipment 3 to 10 5,824 4,541 Construction-in-progress 4,834 2,493 Less accumulated depreciation (33,512 ) (29,927 ) Property and equipment, net $ 30,143 $ 22,942
Other Assets	Other Assets Other assets consist principally of the following as of September 30 (in thousands): 2018 2017 ViaCyte, Inc. $ 479 $ 479 Other noncurrent assets 967 418 Other assets, net $ 1,446 $ 897 The Company has invested a total of $5.3 million in ViaCyte, Inc. (“ViaCyte”), a privately-held California-based biotechnology firm that is developing a unique treatment for diabetes using coated islet cells, the cells that produce insulin in the human body. In fiscal 2006, the Company determined that its investment in ViaCyte was impaired and that the impairment was other-than-temporary. Accordingly, the Company recorded an impairment loss of $4.7 million. In the second quarter of fiscal 2013, the Company recorded an additional other-than-temporary impairment loss on this investment totaling $0.1 million based on a financing round and market valuations. The balance of the investment of $0.5 million, which is accounted for under the cost method, represents less than a 1% ownership interest. The Company does not exert significant influence over ViaCyte’s operating or financial activities. The total carrying value of cost method investments is reviewed quarterly for changes in circumstances or the occurrence of events that suggest the Company’s investment may not be recoverable. The carrying value of cost method investments is not adjusted if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment. In the years ended September 30, 2018, 2017 and 2016, the Company recognized revenue of less than $0.1 million in each period from activity with companies in which it had a strategic investment.
Intangible Assets	Intangible Assets Intangible assets consist principally of acquired patents and technology, customer lists and relationships, licenses and trademarks. The Company recorded amortization expense of $2.7 million, $2.6 million and $2.4 million for the years ended September 30, 2018, 2017 and 2016, respectively. Intangible assets consisted of the following as of September 30 (in thousands): 2018 Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 18,086 $ (9,377 ) $ 8,709 Developed technology 11.5 9,656 (2,361 ) 7,295 Non-compete 5.0 230 (150 ) 80 Patents and other 16.5 2,321 (1,569 ) 752 Subtotal 30,293 (13,457 ) 16,836 Unamortized intangible assets: In-process research and development 267 — 267 Trademarks and trade names 580 — 580 Total $ 31,140 $ (13,457 ) $ 17,683 2017 Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 18,293 $ (7,834 ) $ 10,459 Developed technology 11.7 9,297 (1,478 ) 7,819 Non-compete 5.0 230 (103 ) 127 Patents and other 16.5 2,321 (1,423 ) 898 Subtotal 30,141 (10,838 ) 19,303 Unamortized intangible assets: In-process research and development 679 — 679 Trademarks and trade names 580 — 580 Total $ 31,400 $ (10,838 ) $ 20,562 Based on the intangible assets in service, excluding any possible future amortization associated with acquired (in thousands): 2019 $ 2,690 2020 2,514 2021 2,375 2022 2,336 2023 1,737 Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, completion or abandonment of IPR&D intangible assets, changes in amortization periods, foreign currency exchange rates or other factors. The Company defines IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and is capitalized as an indefinite-lived intangible asset until completion or abandonment of the IPR&D project. Upon completion of the development project (generally when regulatory approval to market the product is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects were abandoned, the related IPR&D assets would be written off. The Company assesses indefinite-lived assets for impairment annually in the fourth quarter and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Similar to the goodwill impairment test, the indefinite-lived assets impairment test requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company performed its annual impairment analysis as of August 31, 2018 and did not record any impairment charges in fiscal 2018 as there were no indicators of impairment associated with the indefinite-lived intangible assets. As a result of the August 31, 2017 impairment analysis, impairment losses on indefinite-lived intangible assets of $0.3 million and $0.1 million were recorded selling, general and administrative expenses, respectively, in the consolidated statements of operations for . No other impairment losses were identified during the annual impairment analyses in fiscal 2018 or 2017.
Goodwill	Goodwill Goodwill represents the excess of the purchase price of an acquired business over the fair value assigned to the assets purchased and liabilities assumed. Goodwill is not amortized but is subject, at a minimum, to annual tests for impairment in accordance with accounting guidance for goodwill. The carrying amount of goodwill is evaluated annually, and between annual evaluations if events occur or circumstances change indicating that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. The Company’s reporting units are the In Vitro Diagnostics and Medical Device operating segments. Inherent in the determination of fair value of the reporting units are certain estimates and judgments, including the interpretation of current economic indicators and market valuations as well as the Company’s strategic plans with regard to its operations. The Company performed its annual assessment of goodwill for impairment as of August 31, 2018 and no goodwill impairment charges were recorded as there were no indicators of impairment associated with either of the reporting units. The impairment assessment is reliant on forecasted cash flows, as well as the selected discount rate when a quantitative assessment is necessary, which are inherently subjective and require significant management estimates. Differences in the reporting units’ actual future operating results as compared with these forecasted estimates could materially affect the estimation of the fair value of the reporting units. The Company did not record any goodwill impairment charges in the years ended September 30, 2018, 2017 or 2016. Goodwill as of September 30, 2018 and 2017 totaled $27.0 million and $27.3 million, respectively. Goodwill related to the In Vitro Diagnostics reporting unit represents the gross value from the acquisition of BioFX Laboratories, Inc. in 2007. As part of the acquisition of Creagh Medical, Ltd. and NorMedix, Inc. in fiscal 2016 (Note 4), the Medical Device reporting segment added $17.9 million of goodwill during fiscal 2016, $13.4 million of which is denominated in Euros and subject to revaluation due to fluctuations in exchange rates. The change in the carrying amount of goodwill by segment for the years ended September 30, 2018 and 2017 was as follows (in thousands) (Dollars in thousands) In Vitro Diagnostics Medical Device Total Balance as of September 30, 2016 $ 8,010 $ 18,545 $ 26,555 Foreign currency translation adjustment — 727 727 Balance as of September 30, 2017 8,010 19,272 27,282 Foreign currency translation adjustment — (250 ) (250 ) Balance as of September 30, 2018 $ 8,010 $ 19,022 $ 27,032
Valuation of Long-Lived Assets	Valuation of Long-Lived Assets Accounting guidance requires the Company to evaluate periodically whether events and circumstances have occurred that may affect the estimated useful life or the recoverability of the remaining balance of long-lived assets, such as property and equipment and intangibles with finite lives. If such events or circumstances were to indicate that the carrying amount of these assets may not be recoverable, the Company would estimate the future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected future cash flows (undiscounted and without interest charges) were less than the carrying amount of the assets, the Company would recognize an impairment charge to reduce such assets to their fair value. In fiscal 2018, 2017 and 2016, there were no impairment charges relating to the Company’s long-lived assets as there were no events or circumstances that occurred that affected the recoverability of such assets.
Accrued Liabilities	Accrued Liabilities Other accrued liabilities consisted of the following as of September 30 (in thousands): 2018 2017 Accrued professional fees $ 311 $ 501 Accrued clinical study expense 2,839 411 Accrued purchases 533 596 Customer claim 1,000 — Construction in progress 1,199 — Deferred rent 121 18 Other 262 247 Total $ 6,265 $ 1,773
Revenue Recognition	Revenue Recognition The Company recognizes revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) shipment has occurred or delivery has occurred if the terms specify destination; (3) the sales price is fixed or determinable; and (4) collectability is reasonably assured. When there are additional performance requirements, revenue is recognized when all such requirements have been satisfied. Under revenue arrangements with multiple deliverables, the Company recognizes each separable deliverable as it is earned. The Company derives its revenue from three primary sources: (1) royalties and license fees from licensing our proprietary surface modification coating, and medical device technologies to customers; (2) product revenue from the sale of reagent chemicals to licensees, the sale of stabilization products, antigens, substrates and surface coatings to the diagnostic and biomedical research markets as well as the sale of medical devices (such as balloons and catheters) and related products to OEM suppliers and distributors; and (3) research and commercial development fees generated on customer projects. Taxes collected from customers and remitted to governmental authorities are excluded from revenue and amounted to $0.1 million for each of the years ended September 30, 2018, 2017 and 2016.
Royalties and license fees	Royalties and license fees . The Company licenses technology to third parties and collects royalties. Sales-based royalty revenue is generated when a customer sells products incorporating the Company’s licensed technologies. Royalty revenue is recognized as licensees report it to the Company, and payment is typically submitted concurrently with the report. For stand-alone license agreements, up-front license fees are recognized based on the terms of the related licensing agreement, either over the term of the agreement or at the point in time when the earnings process is complete. Minimum royalty fees are recognized in the period earned. Revenue related to a performance milestone is recognized upon the achievement of the milestone, as defined in the respective agreements and provided the following conditions have been met: • The milestone payment is non-refundable; • The milestone involved a significant degree of risk, and was not reasonably assured at the inception of the arrangement; • Accomplishment of the milestone involved substantial effort; • The amount of the milestone payment is commensurate with the related effort and risk; and • A reasonable amount of time passed between the initial license payment and the first and subsequent milestone payments. If these conditions have not been met, the milestone payment is deferred and recognized over the term of the agreement.
Product sales	Product sales. Product sales to third parties consist of OEM and distributor sales and are recognized at the time of shipment. The Company’s sales terms provide no right of return outside of the standard warranty policy. Payment terms are generally set at 30-45 days.
Research and development	Research and development. The Company performs third-party research and development activities, which are typically provided on a time and materials basis. Generally, revenue for research and development is recorded as performance progresses under the applicable contract, which corresponds with the period the related costs are incurred.
Arrangements with multiple deliverables	Arrangements with multiple deliverables. Revenue arrangements with multiple deliverables require the Company to: (i) disclose whether multiple deliverables exist, how the deliverables in an arrangement should be separated, and how the consideration should be allocated; (ii) allocate revenue in an arrangement using estimated selling prices (“ESP”) of deliverables if a vendor does not have vendor-specific objective evidence of selling price (“VSOE”) or third-party evidence of selling price (“TPE”); and (iii) allocate revenue using the relative selling price method. The Company accounts for revenue using a multiple attribution model in which consideration allocated to research and development activities is recognized as performed, and milestone payments are recognized when the milestone events are achieved, when such activities and milestones are deemed substantive. Accordingly, in situations where a unit of accounting includes both a license and research and development activities, and when a license does not have stand-alone value, the Company applies a multiple attribution model in which consideration allocated to the license is recognized ratably, consideration allocated to research and development activities is recognized as performed and milestone payments are recognized when the milestone events are achieved, when such activities and milestones are deemed substantive. The Company enters into license and development arrangements that may consist of multiple deliverables which could include license(s) to Surmodics’ technology, research, development and clinical activities, and product sales based on the needs of its customers. For example, a customer may enter into an arrangement to obtain a license to Surmodics’ intellectual property which may also include research, development and clinical activities, as well as supply of products manufactured by Surmodics. For these services provided, Surmodics could receive upfront license fees upon signing of an agreement and granting the license, milestone payments contingent upon advancement of the product through development and clinical stages to successful commercialization, per-unit payments for supply of product, and royalty payments based on customer sales of product incorporating Surmodics’ technology. The Company’s license and development arrangements generally do not have refund provisions if the customer cancels or terminates the agreement. Typically all payments made are non-refundable. The Company is required to evaluate each deliverable in a multiple element arrangement for separability. The Company is then required to allocate revenue to each separate deliverable using a hierarchy of VSOE, TPE, or ESP. In many instances, the Company is not able to establish VSOE for all deliverables in an arrangement with multiple elements. This may be a result of the Company infrequently selling each element separately or having a limited history with multiple element arrangements. When VSOE cannot be established, the Company attempts to establish a selling price of each element based on TPE. TPE is determined based on competitor prices for similar deliverables when sold separately. When the Company is unable to establish a selling price using VSOE or TPE, the Company uses ESP in its allocation of arrangement consideration. The objective of ESP is to determine the price at which the Company would transact a sale if the product or service were sold on a stand-alone basis. ESP is generally used for highly customized offerings. The Company determines ESP for undelivered elements by considering multiple factors including, but not limited to, market conditions, competitive landscape and past pricing arrangements with similar features. The determination of ESP is made through consultation with the Company’s management, taking into consideration the marketing strategies for each business unit.
Deferred Revenue	Deferred Revenue Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated balance sheets, with deferred revenue to be recognized beyond one year being classified as non-current deferred revenue. The Company had deferred revenue of $20.9 million and $0.3 million as of September 30, 2018 and 2017, respectively recorded in current and long-term deferred revenue on the consolidated balance sheets.
Concentrations	Concentrations The Company has licenses and supply agreements with a diverse base of customers and certain customers have multiple products using the Company’s technology. Medtronic plc (“Medtronic”) is the Company’s largest customer at approximately 16%, 18% and 25% of total consolidated revenue for the years ended September 30, 2018, 2017 and 2016, respectively. Medtronic has several separately-licensed products that generate royalty revenue for Surmodics, none of which represented more than 4% of Surmodics’ total revenue. As discussed in Note 3, the Company entered into an agreement with Abbott Vascular, Inc. (“Abbott”) during the year ended September 30, 2018. As a result of revenue recognized under this and other agreements, revenue from Abbott and its affiliates accounted for 11% of consolidated revenue in the year ended September 30, 2018. No other individual customer constitutes more than 10% of the Company’s total revenue. The loss of Medtronic, Abbott or any of our largest customers, or reductions in business from them, could have a material adverse effect on the Company’s business, financial condition, results of operations, and cash flows from operations. The Company’s licensing agreements with many of its customers, including most of its significant customers, cover many licensed products that each separately generates royalty revenue. This structure reduces the potential risk to the Company’s operations that may result from reduced sales (or the termination of a license) of a single product for any specific customer. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy and that credit risk related to accounts receivable is limited due to a large customer base.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method prescribed in accounting guidance. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in this assessment. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in earnings in the period that includes the enactment date of such change.
Research and Development	Research and Development Research and development (“R&D”) costs are expensed as incurred. Some R&D costs are related to customer contracts, and the related revenue is recognized as described in “Revenue Recognition” above. Costs associated with customer-related R&D include specific project direct labor and material expenses as well as an allocation of overhead costs based on direct labor dollars. Clinical trial costs. The Company sponsors clinical trials intended to obtain the necessary clinical data required to obtain approval from various regulatory agencies to market medical devices developed by the Company. Costs associated with clinical trials are included within R&D expense and include trial design and management expenses, clinical site reimbursements and third party fees. The Company’s clinical trials are administered by third-party clinical research organizations (“CROs”). These CROs generally bill monthly for certain services performed as well as upon achievement of certain milestones. The Company monitors patient enrollment, the progress of clinical studies and related activities through internal reviews of data reported to the Company by the CROs and correspondence with the CROs. The Company periodically evaluates its estimates to determine if adjustments are necessary or appropriate based on information it receives. Government funding . The Company is eligible to receive reimbursement for certain qualifying R&D expenditures under a grant from the Industrial Development Agency of Ireland (“IDA”). Reimbursements are recognized as a reduction of R&D expense when there is reasonable assurance that the funding will be received and conditions associated with the funding are met. The Company recorded reimbursements from IDA grants of $0.8 million during each of the years ended September 30, 2018 and 2017 as a reduction of R&D expense. No reimbursements were recorded during fiscal 2016.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates.
Income Per Share Data	Income Per Share Data Basic (loss) income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted income per common share is computed by dividing income by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options and non-vested stock relating to restricted stock awards, restricted stock units and performance shares. However, these items have been excluded from the calculation of diluted net loss per share as their effect is antidilutive for the year ended September 30, 2018, as a result of the net loss incurred for that period. Therefore, diluted weighted average number of shares outstanding and diluted net loss per share were the same as basic weighted average number of shares outstanding and net loss per share for the year ended September 30, 2018. The following table sets forth the denominator for the computation of basic and diluted income per share for each of the years ended September 30 (in thousands): 2018 2017 2016 Net income from continuing operations available to common shareholders $ (4,457 ) $ 3,926 $ 9,985 Basic weighted average shares outstanding 13,157 13,153 12,998 Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units and performance shares — 236 221 Diluted weighted average shares outstanding 13,157 13,389 13,219 The calculation of weighted average diluted shares outstanding excludes outstanding common stock options associated with the right to purchase 0.2 million and 0.7 million shares for fiscal 2017 and 2016, respectively, as their inclusion would have had an antidilutive effect on diluted income per share for those fiscal years.
Currency Translation	Currency Translation The Company’s reporting currency is the U.S. Dollar. Assets and liabilities of non-U.S. dollar functional currency subsidiaries are translated into U.S. dollars at the period-end exchange rates, and revenue and expenses are translated at the average quarterly exchange rates during the period. The net effect of these translation adjustments on the consolidated financial statements is recorded as a foreign currency translation adjustment, a component of accumulated other comprehensive income
New Accounting Pronouncements	New Accounting Pronouncements Accounting Standards to be Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (ASC Topic 606) This accounting standard will be adopted by the Company beginning in the first quarter of fiscal year 2019 (October 1, 2018) using the modified retrospective approach and the impact will be material to the consolidated financial statements due to an anticipated one-quarter acceleration of minimum license fees and sales-based royalty revenue earned under its hydrophilic license agreements. These changes will result in an increase of approximately $5.9 million to retained earnings, including establishment of contract assets on the consolidated balance sheets of $7.6 million and a deferred tax liability of $1.7 million upon adoption. In February 2016, the FASB issued ASU 2016-02, Leases (ASC Topic 842) While the Company is evaluating the impact of the lease guidance on its consolidated financial statements, the Company anticipates that the impact will be material due to the right-of-use assets and lease liabilities related to existing operating leases that will be recorded on the Company’s consolidated balance sheets upon adoption of the standard In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses (ASC Topic 326), Measurement of Credit Losses on Financial Statements Accounting Standards Implemented In January 2017, the FASB issued ASU No. 2017-01, Clarifying the Definition of a Business Business Combinations No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies and Select Balance Sheet Information (Tables)	12 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available for Sale Securities	The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities as of September 30, 2018 and 2017 (in thousands): September 30, 2018 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper and corporate bonds $ 41,403 $ — $ (51 ) $ 41,352 Total $ 41,403 $ — $ (51 ) $ 41,352 September 30, 2017 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper and corporate bonds $ 31,817 $ — $ (15 ) $ 31,802 Total $ 31,817 $ — $ (15 ) $ 31,802
Components of Inventories	Inventories consisted of the following components as of September 30 (in thousands): 2018 2017 Raw materials $ 1,890 $ 1,603 Work in-process 780 659 Finished products 1,346 1,254 Total $ 4,016 $ 3,516
Schedule of Property, Plant and Equipment	Property and equipment consisted of the following components as of September 30 (in thousands): Useful Life 2018 2017 (In years) Land N/A $ 4,420 $ 4,420 Laboratory fixtures and equipment 3 to 10 22,024 19,491 Buildings and improvements 3 to 20 21,717 21,924 Leasehold improvements 10 4,836 — Office furniture and equipment 3 to 10 5,824 4,541 Construction-in-progress 4,834 2,493 Less accumulated depreciation (33,512 ) (29,927 ) Property and equipment, net $ 30,143 $ 22,942
Summary of Other Assets	Other assets consist principally of the following as of September 30 (in thousands): 2018 2017 ViaCyte, Inc. $ 479 $ 479 Other noncurrent assets 967 418 Other assets, net $ 1,446 $ 897
Schedule of Intangible Assets	Intangible assets consisted of the following as of September 30 (in thousands): 2018 Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 18,086 $ (9,377 ) $ 8,709 Developed technology 11.5 9,656 (2,361 ) 7,295 Non-compete 5.0 230 (150 ) 80 Patents and other 16.5 2,321 (1,569 ) 752 Subtotal 30,293 (13,457 ) 16,836 Unamortized intangible assets: In-process research and development 267 — 267 Trademarks and trade names 580 — 580 Total $ 31,140 $ (13,457 ) $ 17,683 2017 Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 18,293 $ (7,834 ) $ 10,459 Developed technology 11.7 9,297 (1,478 ) 7,819 Non-compete 5.0 230 (103 ) 127 Patents and other 16.5 2,321 (1,423 ) 898 Subtotal 30,141 (10,838 ) 19,303 Unamortized intangible assets: In-process research and development 679 — 679 Trademarks and trade names 580 — 580 Total $ 31,400 $ (10,838 ) $ 20,562
Estimated Amortization Expense	Based on the intangible assets in service, excluding any possible future amortization associated with acquired (in thousands): 2019 $ 2,690 2020 2,514 2021 2,375 2022 2,336 2023 1,737
Schedule Of Carrying Amount Of Goodwill By Segment	The change in the carrying amount of goodwill by segment for the years ended September 30, 2018 and 2017 was as follows (in thousands) (Dollars in thousands) In Vitro Diagnostics Medical Device Total Balance as of September 30, 2016 $ 8,010 $ 18,545 $ 26,555 Foreign currency translation adjustment — 727 727 Balance as of September 30, 2017 8,010 19,272 27,282 Foreign currency translation adjustment — (250 ) (250 ) Balance as of September 30, 2018 $ 8,010 $ 19,022 $ 27,032
Schedule of Other Accrued Liabilities	Other accrued liabilities consisted of the following as of September 30 (in thousands): 2018 2017 Accrued professional fees $ 311 $ 501 Accrued clinical study expense 2,839 411 Accrued purchases 533 596 Customer claim 1,000 — Construction in progress 1,199 — Deferred rent 121 18 Other 262 247 Total $ 6,265 $ 1,773
Denominator for Computation of Basic and Diluted Income Per Share	The following table sets forth the denominator for the computation of basic and diluted income per share for each of the years ended September 30 (in thousands): 2018 2017 2016 Net income from continuing operations available to common shareholders $ (4,457 ) $ 3,926 $ 9,985 Basic weighted average shares outstanding 13,157 13,153 12,998 Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units and performance shares — 236 221 Diluted weighted average shares outstanding 13,157 13,389 13,219

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Sep. 30, 2018
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Summary of Purchase Price	The purchase price of Creagh Medical consisted of the following (in thousands) Cash paid $ 18,449 Debt assumed 761 Contingent consideration 9,064 Total purchase price 28,274 Less cash and cash equivalents acquired (251 ) Total purchase price, net of cash acquired $ 28,023
Schedule of Purchase Price to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed	The following table summarizes the final allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the Creagh Medical acquisition: Fair Value (Dollars in thousands) Estimated Useful Life (In years) Current assets $ 896 N/A Property and equipment 634 1.0-10.0 Trade name 75 N/A Developed technology 1,787 7.0 In-process research and development 942 N/A Customer relationships 11,119 7.0-10.0 Other noncurrent assets 81 N/A Current liabilities (942 ) N/A Deferred tax liabilities (9 ) N/A Net assets acquired 14,583 Goodwill 13,440 N/A Total purchase price, net of cash acquired $ 28,023
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Summary of Purchase Price	The purchase price of NorMedix consisted of the following (in thousands) Cash paid $ 6,905 Contingent consideration 3,520 Total purchase price 10,425 Less cash and cash equivalents acquired (17 ) Total purchase price, net of cash acquired $ 10,408
Schedule of Purchase Price to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed	The following table summarizes the allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the NorMedix acquisition: Fair Value (Dollars in thousands) Estimated Useful Life (In years) Net current assets $ 113 N/A Property and equipment 60 7.0 Developed technology 6,850 10.0-14.0 Customer relationships 900 4.0 Deferred tax asset 690 N/A Other noncurrent asset 13 N/A Accounts payable (187 ) N/A Deferred tax liabilities (2,483 ) N/A Net assets acquired 5,956 Goodwill 4,452 N/A Total purchase price, net of cash acquired $ 10,408
Creagh Medical and NorMedix [Member]
Business Acquisition [Line Items]
Schedule of Pro Forma Financial Information	Years Ended September 30, 2016 (In thousands, except per share data) (Unaudited) Revenue $ 72,416 Income from continuing operations 10,590 Loss from discontinued operations, net of income taxes — Net income $ 12,315 Per share amounts: Basic net income per share $ 0.95 Diluted net income per share $ 0.93

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2018 (in thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value as of September 30, 2018 Assets Cash equivalents $ — $ 13,999 $ — $ 13,999 Available-for-sale securities — 41,352 $ 41,352 Total assets $ — $ 55,351 $ — $ 55,351 Liabilities Contingent consideration $ — $ — $ (14,466 ) $ (14,466 ) Total liabilities $ — $ — $ (14,466 ) $ (14,466 ) The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2017 (in thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value as of September 30, 2017 Assets Cash equivalents $ — $ 6,639 $ — $ 6,639 Available-for-sale securities — 31,802 $ 31,802 Total assets $ — $ 38,441 $ — $ 38,441 Liabilities Contingent consideration $ — $ — $ (14,864 ) $ (14,864 ) Total liabilities $ — $ — $ (14,864 ) $ (14,864 )
Schedule of Contingent Consideration Liability	The following table summarizes the changes in the contingent consideration liability for the years ended September 30, 2018 and 2017: (Dollars in thousands) Contingent consideration liability at September 30, 2016 $ 14,517 Additions — Fair value adjustments (2,350 ) Settlements — Interest accretion 2,223 Foreign currency translation 474 Contingent consideration liability at September 30, 2017 14,864 Additions — Fair value adjustments 288 Settlements (925 ) Interest accretion 387 Foreign currency translation (148 ) Contingent consideration liability at September 30, 2018 $ 14,466

Stock-Based Compensation Plans

Stock-Based Compensation Plans (Tables)	12 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation Expenses	The Company’s stock-based compensation expenses for the years ended September 30 were allocated to the following expense categories 2018 2017 2016 Product costs $ 69 $ 90 $ 22 Research and development 801 510 324 Selling, general and administrative 3,937 2,872 3,498 Total stock-based compensation expense $ 4,807 $ 3,472 $ 3,844
Assumptions Used in Stock Option Plans	The assumptions used as inputs in the model for the years ended September 30 were as follows: 2018 2017 2016 Risk-free interest rates 2.18 % 1.74 % 1.89 % Expected life 4.8 years 4.6 years 4.6 years Expected volatility 33 % 34 % 37 % Dividend yield 0 % 0 % 0 %
Schedule of Stock Option Activity	The following table summarizes all stock options activity and stock options outstanding and exercisable under the stock option plans during fiscal 2018, 2017 and 2016: Number of Shares Weighted Average Exercise Price Outstanding at September 30, 2015 1,118,008 $ 20.10 Granted 241,582 20.63 Exercised (437,850 ) 15.68 Forfeited and expired (94,415 ) 31.52 Outstanding at September 30, 2016 827,325 21.30 Granted 229,039 24.08 Exercised (6,819 ) 13.89 Forfeited and expired (47,640 ) 30.65 Outstanding at September 30, 2017 1,001,905 21.54 Granted 269,961 34.08 Exercised (450,495 ) 19.46 Forfeited and expired (110,825 ) 30.18 Outstanding at September 30, 2018 710,546 26.28 Exercisable at September 30, 2018 236,302 $ 22.33
Schedule of Restricted Stock Awards Activity	The following table summarizes all restricted stock awards activity during fiscal 2018, 2017 and 2016: Number of Shares Weighted Average Grant Price Balance at September 30, 2015 27,775 $ 22.12 Granted 20,108 20.14 Vested (12,311 ) 22.19 Forfeited (2,439 ) 21.17 Balance at September 30, 2016 33,133 20.96 Granted 51,559 25.12 Vested (14,497 ) 21.10 Forfeited (2,278 ) 25.12 Balance at September 30, 2017 67,917 23.98 Granted 56,244 34.38 Vested (28,717 ) 23.78 Forfeited (10,020 ) 29.10 Balance at September 30, 2018 85,424 $ 30.30
Schedule of Fair Value at the Date of Grant	The aggregate number of shares that could be awarded to key employees if the minimum, target and maximum performance goals are met, based upon the fair value at the date of grant is as follows: Performance Period Minimum Shares Target Shares Maximum Shares Fiscal 2016 - 2018 11,910 59,548 119,096 Fiscal 2017 - 2019 9,352 46,758 93,516

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Schedule of Income Taxes from Continuing Operations	Income taxes from continuing operations in the accompanying consolidated statements of operations for the years ended September 30 are as follows (in thousands): 2018 2017 2016 Current (benefit) provision: U.S. Federal $ (890 ) $ 2,125 $ 6,550 U.S. State 51 (72 ) 250 International 41 54 (98 ) Total current (benefit) provision (798 ) 2,107 6,702 Deferred (benefit) provision: U.S. Federal (2,006 ) 1,085 169 U.S. State (271 ) (85 ) (43 ) International — — 135 Total deferred (benefit) provision (2,277 ) 1,000 261 Total (benefit) provision $ (3,075 ) $ 3,107 $ 6,963
Schedule of Reconciliation Difference of Income Taxes	The reconciliation of the difference between amounts calculated at the statutory U.S. federal tax rate of 24.5%, 35% and 35% for fiscal 2018, 2017 and 2016, respectively, and the Company’s effective tax rate from continuing operations is as follows (in thousands) : 2018 2017 2016 Amount at statutory U.S. federal income tax rate $ (1,845 ) $ 2,461 $ 5,932 Change because of the following items: State income taxes, net of federal benefit (724 ) (13 ) 142 Stock-based compensation (2,063 ) 330 (607 ) Valuation allowance change 960 665 (2,500 ) Tax reserve change 158 (52 ) 258 Federal manufacturing deduction — (313 ) (280 ) U.S. Federal and foreign research and development credits (1,710 ) (706 ) (571 ) Gain on strategic investment and corporate subsidiary — — 2,630 Foreign rate differential 371 948 622 Acquisition-related transaction costs — — 768 Contingent consideration expense (gain) 165 (45 ) 522 Unrealized foreign currency exchange (gain) loss on contingent consideration obligation (23 ) 170 — Federal and state rate change 1,582 — — Other 54 (338 ) 47 Income tax (benefit) provision $ (3,075 ) $ 3,107 $ 6,963
Schedule of Deferred Income Taxes	The components of deferred income taxes consisted of the following as of September 30 and result from differences in the recognition of transactions for income tax and financial reporting purposes (in thousands): 2018 2017 Depreciable assets $ (1,019 ) $ (3,335 ) Accruals and reserves 1,308 1,123 Stock-based compensation 1,798 3,370 Impaired strategic investments 1,687 2,701 NOL carryforwards 4,637 3,627 U.S. Federal and state R&D credits 1,896 242 Other 538 810 Valuation allowance (4,541 ) (4,511 ) Total deferred tax assets $ 6,304 $ 4,027
Summary of Reconciliation of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, is as follows (in thousands): 2018 2017 2016 Beginning of fiscal year $ 1,481 $ 1,508 $ 1,248 Increases in tax positions for prior years 61 8 77 Decreases in tax positions for prior years — (35 ) (21 ) Increases in tax positions for current year 735 216 365 Settlements with taxing authorities (613 ) — — Lapse of the statute of limitations (105 ) (216 ) (161 ) End of fiscal year $ 1,559 $ 1,481 $ 1,508

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Summary of Annual Commitments Pursuant to Operating Lease Agreements	Annual commitments pursuant to operating lease agreements in place as of September 30, 2018 are as follows (in thousands): Year Ended September 30, 2019 $ 443 2020 452 2021 396 2022 391 2023 399 Thereafter 1,933 Total minimum lease payments $ 4,014

Reportable Segment Information

Reportable Segment Information (Tables)	12 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Segment Revenue, Operating Income and Depreciation and Amortization	The tables below present segment revenue, operating income from continuing operations and depreciation and amortization, for the years ended September 30, as follows (in thousands): 2018 2017 2016 Revenue: Medical Device $ 60,513 $ 53,983 $ 53,202 In Vitro Diagnostics 20,823 19,129 18,164 Total revenue $ 81,336 $ 73,112 $ 71,366 Operating (loss) income: Medical Device $ (8,478 ) $ 6,902 $ 16,975 In Vitro Diagnostics 8,619 8,293 7,115 Total segment operating income 141 15,195 24,090 Corporate (8,940 ) (8,092 ) (7,231 ) Total operating (loss) income $ (8,799 ) $ 7,103 $ 16,859 Depreciation and amortization: Medical Device $ 5,376 $ 4,453 $ 3,261 In Vitro Diagnostics 394 412 789 Corporate 661 690 823 Total depreciation and amortization $ 6,431 $ 5,555 $ 4,873
Revenue from Major Customers	Revenue from customers that equaled or exceeded 10% of total revenue was as follows for the years ended September 30: 2018 2017 2016 Medtronic 16 % 18 % 25 % Abbott 11 % N/A N/A
Geographic Revenue and Long-lived Assets	Geographic revenue was as follows for the years ended September 30: 2018 2017 2016 Domestic 79 % 77 % 79 % Foreign 21 % 23 % 21 % Long-lived assets, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, by country were as follows as of September 30: 2018 2017 U.S. $ 26,652 $ 20,949 Ireland 21,174 22,555

Quarterly Financial Data (Una_2

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Sep. 30, 2018
Quarterly Financial Information Disclosure [Abstract]
Summary of Unaudited Quarterly Results	The following is a summary of the unaudited quarterly results for the years ended September 30, 2018 and 2017 (in thousands, except per share data). First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal 2018 Total revenue $ 17,013 $ 19,058 $ 22,227 $ 23,038 Operating (loss) income (633 ) 525 (6,250 ) (2,441 ) Net (loss) income (1,556 ) 1,534 (2,682 ) (1,753 ) Basic net (loss) income per share (1): (0.12 ) 0.12 (0.20 ) (0.13 ) Diluted net (loss) income per share (1): (0.12 ) 0.11 (0.20 ) (0.13 ) Fiscal 2017 Total revenue $ 17,761 $ 17,503 $ 17,790 $ 20,058 Operating income 3,268 1,677 1,743 415 Net income 2,300 506 720 400 Basic net income per share (1): 0.17 0.04 0.05 0.03 Diluted net income per share (1): 0.17 0.04 0.05 0.03 (1) The sum of the quarterly net (loss) income per share amounts may not equal the annual income per share total because of changes in the weighted average number of shares outstanding that occurred during the year.

Schedule of Valuation and Qua_2

Schedule of Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Detail) - Allowance for doubtful accounts [Member] - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ 230	$ 19	$ 10
Additions Charged (Credited) to Expenses	64	222	9
Deductions From Reserves	147	11
Balance at End of Period	$ 147	$ 230	$ 19

Summary of Significant Accoun_4

Summary of Significant Accounting Policies and Select Balance Sheet Information - Additional Information (Detail) - USD ($) shares in Millions	Aug. 31, 2018	Mar. 31, 2013	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2006
Summary Of Significant Accounting Policies [Line Items]
Net unrealized loss reclassified out of accumulated other comprehensive income with a corresponding adjustment to other income (loss)			$ 0	$ 0	$ 0
Held-to-maturity debt securities			0	0
Realized gains or losses on sales of available-for-sale securities			0	0	0
Depreciation expense			3,700,000	3,000,000	2,300,000
Amortization expense			2,700,000	2,600,000	2,400,000
Impairment loss			0
Other impairment losses			0	0
Goodwill impairment charges	$ 0		0	0	0
Goodwill			27,032,000	27,282,000	26,555,000
Goodwill subject to revaluation due to fluctuations in exchange rates			13,400,000
Impairment charges relating to long-lived assets			0	0	0
Taxes collected from customers and remitted to governmental authorities			100,000	$ 100,000	$ 100,000
Weighted average diluted shares outstanding excluded outstanding stock options				0.2	0.7
Accounting Standards Update 2014-09 [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated change to retained earnings due to adoption of new accounting standard			5,900,000
Contract asset			7,600,000
Deferred tax liabilities			1,700,000
IDA [Member]
Summary Of Significant Accounting Policies [Line Items]
Reimbursement recorded as reduction to R&D expense			$ 800,000	$ 800,000	$ 0
Customer Concentration Risk [Member] | Revenue [Member] | Medtronic [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of revenue			16.00%	18.00%	25.00%
Customer Concentration Risk [Member] | Revenue [Member] | Abbott [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of revenue			11.00%
Other Accrued Liabilities, Current and Other Long-term Liabilities [Member]
Summary Of Significant Accounting Policies [Line Items]
Deferred revenue			$ 20,900,000	$ 300,000
Medical Device [Member]
Summary Of Significant Accounting Policies [Line Items]
Goodwill			19,022,000	19,272,000	$ 18,545,000
Additions to goodwill					17,900,000
Research and development [Member] | In-Process Research and Development [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment loss				300,000
Selling, General and Administrative Expenses [Member] | In-Process Research and Development [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment loss				100,000
ViaCyte, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Equity method investment			5,300,000
Impairment loss on investment		$ 100,000				$ 4,700,000
Cost method of investment			500,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized from activity with companies in which it had strategic investment			$ 100,000	$ 100,000	$ 100,000
Product sales payment terms			45 days
Maximum [Member] | Customer Concentration Risk [Member] | Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of revenue			10.00%
Maximum [Member] | Product Concentration Risk [Member] | Revenue [Member] | Medtronic [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of revenue			4.00%
Maximum [Member] | ViaCyte, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Company's ownership percentage			1.00%
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Product sales payment terms			30 days
Leasehold Improvements [Member]
Summary Of Significant Accounting Policies [Line Items]
Amortization period			Leasehold improvements are amortized over the shorter of the term of the lease or the estimated useful life of the asset.

Summary of Significant Accoun_5

Summary of Significant Accounting Policies and Select Balance Sheet Information - Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 41,403	$ 31,817
Unrealized Losses	(51)	(15)
Fair Value	41,352	31,802
Commercial paper and corporate bonds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	41,403	31,817
Unrealized Losses	(51)	(15)
Fair Value	$ 41,352	$ 31,802

Summary of Significant Accoun_6

Summary of Significant Accounting Policies and Select Balance Sheet Information - Components of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 1,890	$ 1,603
Work in-process	780	659
Finished products	1,346	1,254
Total	$ 4,016	$ 3,516

Summary of Significant Accoun_7

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Line Items]
Less accumulated depreciation	$ (33,512)	$ (29,927)
Property and equipment, net	30,143	22,942
Land [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	4,420	4,420
Laboratory Fixtures and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 22,024	19,491
Laboratory Fixtures and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	3 years
Laboratory Fixtures and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	10 years
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 21,717	21,924
Building and Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	3 years
Building and Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	20 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	10 years
Property and Equipment, Gross	$ 4,836
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 5,824	4,541
Office Furniture and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	3 years
Office Furniture and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	10 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 4,834	$ 2,493

Summary of Significant Accoun_8

Summary of Significant Accounting Policies and Select Balance Sheet Information - Summary of Other Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017
Schedule of Investments [Line Items]
Other assets, net	$ 1,446	$ 897
ViaCyte, Inc. [Member]
Schedule of Investments [Line Items]
Other assets, net	479	479
Other Noncurrent Assets [Member]
Schedule of Investments [Line Items]
Other assets, net	$ 967	$ 418

Summary of Significant Accoun_9

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Intangible Assets [Line Items]
Definite-lived intangible assets, Accumulated Amortization	$ (13,457)	$ (10,838)
Intangible assets, Gross Carrying Amount	31,140	31,400
Intangible assets, Net	$ 17,683	$ 20,562
Customer Lists and Relationships [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years 10 months 24 days	8 years 10 months 24 days
Definite-lived intangible assets, Gross Carrying Amount	$ 18,086	$ 18,293
Definite-lived intangible assets, Accumulated Amortization	(9,377)	(7,834)
Definite-lived intangible assets, Net	$ 8,709	$ 10,459
Developed Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	11 years 6 months	11 years 8 months 12 days
Definite-lived intangible assets, Gross Carrying Amount	$ 9,656	$ 9,297
Definite-lived intangible assets, Accumulated Amortization	(2,361)	(1,478)
Definite-lived intangible assets, Net	$ 7,295	$ 7,819
Non-compete [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	5 years	5 years
Definite-lived intangible assets, Gross Carrying Amount	$ 230	$ 230
Definite-lived intangible assets, Accumulated Amortization	(150)	(103)
Definite-lived intangible assets, Net	$ 80	$ 127
Patents and Other [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	16 years 6 months	16 years 6 months
Definite-lived intangible assets, Gross Carrying Amount	$ 2,321	$ 2,321
Definite-lived intangible assets, Accumulated Amortization	(1,569)	(1,423)
Definite-lived intangible assets, Net	752	898
Definite-Lived Intangible Assets [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Gross Carrying Amount	30,293	30,141
Definite-lived intangible assets, Accumulated Amortization	(13,457)	(10,838)
Definite-lived intangible assets, Net	16,836	19,303
In-Process Research and Development [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	267	679
Trademarks and Trade Names [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	$ 580	$ 580

Summary of Significant Accou_10

Summary of Significant Accounting Policies and Select Balance Sheet Information - Estimated Amortization Expense (Detail) $ in Thousands	Sep. 30, 2018USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
2,019	$ 2,690
2,020	2,514
2,021	2,375
2,022	2,336
2,023	$ 1,737

Summary of Significant Accou_11

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule Of Carrying Amount of Goodwill by Segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Goodwill [Line Items]
Beginning Balance	$ 27,282	$ 26,555
Foreign currency translation adjustment	(250)	727
Ending Balance	27,032	27,282
In Vitro Diagnostics [Member]
Goodwill [Line Items]
Beginning Balance	8,010	8,010
Ending Balance	8,010	8,010
Medical Device [Member]
Goodwill [Line Items]
Beginning Balance	19,272	18,545
Foreign currency translation adjustment	(250)	727
Ending Balance	$ 19,022	$ 19,272

Summary of Significant Accou_12

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule of Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017
Accrued Liabilities Current [Abstract]
Accrued professional fees	$ 311	$ 501
Accrued clinical study expense	2,839	411
Accrued purchases	533	596
Customer claim	1,000
Construction in progress	1,199
Deferred rent	121	18
Other	262	247
Total	$ 6,265	$ 1,773

Summary of Significant Accou_13

Summary of Significant Accounting Policies and Select Balance Sheet Information - Denominator for Computation of Basic and Diluted Income Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Net income from continuing operations available to common shareholders	$ (4,457)	$ 3,926	$ 9,985
Basic weighted average shares outstanding	13,157	13,153	12,998
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units and performance shares		236	221
Diluted weighted average shares outstanding	13,157	13,389	13,219

Collaborative Arrangement - Add

Collaborative Arrangement - Additional Information (Detail) - Abbott [Member]	12 Months Ended
	Sep. 30, 2018USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront fee received	$ 25,000,000
Collaboration revenue recognized	4,400,000
Deferred revenue, current	9,600,000
Long-term deferred revenue	11,100,000
Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement additional potential milestone payments receivable	$ 67,000,000

Business Combinations - Additio

Business Combinations - Additional Information (Detail) $ in Thousands, € in Millions	Jan. 08, 2016USD ($)	Nov. 20, 2015USD ($)	Nov. 20, 2015EUR (€)	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2018EUR (€)	Nov. 20, 2015EUR (€)
Business Acquisition [Line Items]
Acquisition transaction, integration and other costs																$ 3,187
Business acquisition, revenue recognized				$ 23,038	$ 22,227	$ 19,058	$ 17,013	$ 20,058	$ 17,790	$ 17,503	$ 17,761			$ 81,336	$ 73,112	71,366
Business acquisition, loss recognized				(1,753)	$ (2,682)	$ 1,534	$ (1,556)	$ 400	$ 720	$ 506	$ 2,300			(4,457)	$ 3,926	9,985
Contingent payments upon achievement of strategic milestones														925		305
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Outstanding common shares and voting shares percentage		100.00%																100.00%
Payments to acquire business														28,274
Upfront payments		$ 19,300	€ 18											18,449
Contingent milestone payments		12,800																€ 12
Contingent payments upon achievement of milestones				$ 11,100										11,100
Acquisition transaction, integration and other costs																2,700
Business acquisition, revenue recognized													$ 3,300
Business acquisition, loss recognized													$ (2,700)
Creagh Medical Ltd [Member] | Scenario Forecast [Member]
Business Acquisition [Line Items]
Contingent payments upon achievement of milestones | €																	€ 9.6
Creagh Medical Ltd [Member] | Maximum [Member]
Business Acquisition [Line Items]
Payments to acquire business		$ 32,000	€ 30
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Outstanding common shares and voting shares percentage	100.00%
Payments to acquire business														10,425
Upfront payments	$ 7,000													6,905
Contingent milestone payments	7,000
Acquisition transaction, integration and other costs																300
Business acquisition, revenue recognized												$ 900
Business acquisition, loss recognized												$ (400)
Contingent payments upon achievement of strategic milestones														$ 900
NorMedix, Inc. [Member] | Maximum [Member]
Business Acquisition [Line Items]
Payments to acquire business	$ 14,000
Creagh Medical and NorMedix [Member] | Unaudited Pro Forma [Member]
Business Acquisition [Line Items]
Amortization expense on intangible assets																2,800
Contingent consideration accretion expense																1,800
Non-recurring professional fees																3,200
Tax effect impact																$ 200

Business Combinations - Summary

Business Combinations - Summary of Purchase Price (Detail) $ in Thousands, € in Millions	Jan. 08, 2016USD ($)	Nov. 20, 2015USD ($)	Nov. 20, 2015EUR (€)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)
Business Acquisition [Line Items]
Contingent consideration				$ 14,500	$ 14,900
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Cash Paid		$ 19,300	€ 18	18,449
Debt assumed				761
Contingent consideration				9,064
Total purchase price				28,274
Less cash and cash equivalents acquired				(251)
Total purchase price, net of cash acquired				28,023
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Cash Paid	$ 7,000			6,905
Contingent consideration				3,520
Total purchase price				10,425
Less cash and cash equivalents acquired				(17)
Total purchase price, net of cash acquired				$ 10,408

Business Combinations - Summa_2

Business Combinations - Summary of Purchase Price Allocation to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Business Acquisition [Line Items]
Goodwill	$ 27,032	$ 27,282	$ 26,555
Developed Technology [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	11 years 6 months	11 years 8 months 12 days
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Current assets	$ 896
Property and equipment	634
Other noncurrent assets	81
Current liabilities	(942)
Deferred tax liabilities	(9)
Net assets acquired	14,583
Goodwill	13,440
Total purchase price, net of cash acquired	$ 28,023
Creagh Medical Ltd [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	1 year
Creagh Medical Ltd [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
Creagh Medical Ltd [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Intangible assets	$ 1,787
Estimated Useful Life (In years)	7 years
Creagh Medical Ltd [Member] | In-Process Research and Development [Member]
Business Acquisition [Line Items]
Intangible assets	$ 942
Creagh Medical Ltd [Member] | Customer Relationship [Member]
Business Acquisition [Line Items]
Intangible assets	$ 11,119
Creagh Medical Ltd [Member] | Customer Relationship [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	7 years
Creagh Medical Ltd [Member] | Customer Relationship [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
Creagh Medical Ltd [Member] | Trade Name [Member]
Business Acquisition [Line Items]
Intangible assets	$ 75
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Current assets	113
Property and equipment	60
Deferred tax asset	690
Other noncurrent assets	13
Accounts payable	(187)
Deferred tax liabilities	(2,483)
Net assets acquired	5,956
Goodwill	4,452
Total purchase price, net of cash acquired	$ 10,408
Estimated Useful Life (In years)	7 years
NorMedix, Inc. [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Intangible assets	$ 6,850
NorMedix, Inc. [Member] | Developed Technology [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
NorMedix, Inc. [Member] | Developed Technology [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	14 years
NorMedix, Inc. [Member] | Customer Relationship [Member]
Business Acquisition [Line Items]
Intangible assets	$ 900
Estimated Useful Life (In years)	4 years

Business Combinations - Pro For

Business Combinations - Pro Forma Financial Information (Detail) - Creagh Medical and NorMedix [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Sep. 30, 2016USD ($)$ / shares
Business Acquisition [Line Items]
Revenue	$ 72,416
Income from continuing operations	10,590
Net income	$ 12,315
Per share amounts:
Basic net income per share | $ / shares	$ 0.95
Diluted net income per share | $ / shares	$ 0.93

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) € in Millions	12 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2018EUR (€)	Sep. 30, 2018EUR (€)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liability	$ 14,500,000	$ 14,900,000
Contingent consideration liability, noncurrent	3,425,000	13,114,000
Level 3 assets	0	0
Transfers in or out Level 3, Assets	0	0
Transfers in or out Level 3, Liabilities	$ 0	$ 0
Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of Probability Achievement of Contingent Consideration payment.	5.00%	25.00%
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of Probability Achievement of Contingent Consideration payment.	95.00%	100.00%
Contingent Consideration [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Foreign currency gains (losses)	$ 100,000	$ (500,000)	$ (400,000)
Contingent Consideration [Member] | Revenue Based Milestones [Member] | Discount Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement inputs	20.5				20.5
Contingent Consideration [Member] | Non Revenue Based Milestones [Member] | Discount Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement inputs	6				6
Contingent Consideration [Member] | Minimum [Member] | Revenue Based Milestones [Member] | Discount Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement inputs		14
Contingent Consideration [Member] | Minimum [Member] | Non Revenue Based Milestones [Member] | Discount Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement inputs		2.7
Contingent Consideration [Member] | Maximum [Member] | Revenue Based Milestones [Member] | Discount Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement inputs		23.5
Contingent Consideration [Member] | Maximum [Member] | Non Revenue Based Milestones [Member] | Discount Rate [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value measurement inputs		3
Creagh Medical Ltd [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liability	$ 9,064,000
Contingent consideration related to acquisition	$ 11,000,000				€ 9.6
Business combination contingent consideration liability percentage	2.30%				2.30%
Scenario Forecast [Member] | Creagh Medical Ltd [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration related to acquisition | €				€ 9.6

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Member] - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	$ 55,351	$ 38,441
Liabilities measured at fair value	(14,466)	(14,864)
Available-for-sale securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	41,352	31,802
Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	13,999	6,639
Contingent consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	(14,466)	(14,864)
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	55,351	38,441
Significant Other Observable Inputs (Level 2) [Member] | Available-for-sale securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	41,352	31,802
Significant Other Observable Inputs (Level 2) [Member] | Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	13,999	6,639
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	(14,466)	(14,864)
Significant Unobservable Inputs (Level 3) [Member] | Contingent consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	$ (14,466)	$ (14,864)

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Contingent Consideration Liability (Detail) - Contingent Consideration [Member] - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Contingent consideration liability, beginning balance	$ 14,864	$ 14,517
Fair value adjustments	288	(2,350)
Settlements	(925)
Interest accretion	387	2,223
Foreign currency translation	(148)	474
Contingent consideration liability, ending balance	$ 14,466	$ 14,864

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2018	Nov. 06, 2015	Nov. 05, 2014
Stockholders Equity [Line Items]
Payments for repurchase of common stock	$ 4,702,000
Common stock repurchased, Shares	196,190
Stock repurchased average price per share	$ 23.97
Remaining amount available for repurchases of shares		$ 25,300,000
Accelerated Share Repurchase Program [Member]
Stockholders Equity [Line Items]
Maximum payments for repurchase of common stock			$ 20,000,000	$ 30,000,000

Stock-Based Compensation Plan_2

Stock-Based Compensation Plans - Stock-based Compensation Expenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 4,807	$ 3,472	$ 3,844
Product costs [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	69	90	22
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	801	510	324
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 3,937	$ 2,872	$ 3,498

Stock-Based Compensation Plan_3

Stock-Based Compensation Plans - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015
Stock-Based Compensation Activity [Line Items]
Unrecognized compensation costs related to non-vested awards		$ 5,700,000
Weighted average period for recognition of compensation costs related to non-vested awards		2 years 1 month 6 days
Performance share awards fully expensed		$ 600,000
Weighted average per share fair value of stock options		$ 10.91	$ 7.63	$ 6.95
Dividend rates		0.00%	0.00%	0.00%
Stock option exercisable on a pro-rata basis		3 years 9 months 18 days
Vesting period		3 years	3 years	3 years
Aggregate intrinsic value of the option shares outstanding		$ 34,400,000
Aggregate intrinsic value of the option shares exercisable		$ 12,400,000
Remaining contractual life of options outstanding		4 years 10 months 24 days
Total pre-tax intrinsic value of options exercised		$ 12,100,000	$ 100,000	$ 5,100,000
Fiscal 2014 (2014 - 2016) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year		2,014
Performance period end year		2,016
Fiscal 2015 (2015 - 2017) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year		2,015
Performance period end year		2,017
Fiscal 2016 (2016 - 2018) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year		2,016
Performance period end year		2,018
Fiscal 2016 (2016 - 2018) [Member] | Scenario Forecast [Member]
Stock-Based Compensation Activity [Line Items]
Maximum estimated shares earned	76,400
Fiscal 2017 (2016 - 2018) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year		2,016
Performance period end year		2,018
Fiscal 2017 (2017 - 2019) [Member]
Stock-Based Compensation Activity [Line Items]
Maximum estimated shares earned		78,226
Nonqualified Stock Options [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized		$ 1,600,000	1,300,000	1,200,000
Nonqualified Stock Options [Member] | Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period		4 years
Nonqualified Stock Options [Member] | Minimum [Member] | Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option expiration term upon expiration of employment or service		7 years
Nonqualified Stock Options [Member] | Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Stock option exercisable on a pro-rata basis		1 year
Restricted Stock Awards [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period		3 years
Restricted stock expense		$ 1,000,000	$ 500,000	$ 300,000
Number of stock units awarded		56,244	51,559	20,108
Number of stock units forfeited		10,020	2,278	2,439
Number of stock units outstanding		85,424	67,917	33,133	27,775
Performance Shares [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized		$ 1,500,000	$ 1,200,000	$ 1,900,000
Performance shares forfeited		12,217
Performance Shares [Member] | Fiscal 2016 (2016 - 2018) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded				1,300,000
Performance Shares [Member] | Fiscal 2017 (2016 - 2018) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded			1,200,000
1999 Employee Stock Purchase Plan [Member]
Stock-Based Compensation Activity [Line Items]
Annual compensation withheld, maximum limit		$ 25,000
1999 Employee Stock Purchase Plan [Member] | Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Common stock authorized, shares		600,000
Stock compensation expenses recognized		$ 100,000	100,000	100,000
Annual compensation withheld		10.00%
Employee contributions		$ 100,000	100,000
Vesting Anniversary [Member] | Nonqualified Stock Options [Member] | Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage		25.00%
Vesting Anniversary [Member] | Restricted Stock Awards [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage		33.00%
Performance Level [Member] | Minimum [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage		20.00%
Performance Level [Member] | Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Performance share awards, estimated vesting percentage		200.00%
2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Common stock authorized, shares		2,000,000
Number of shares available for future awards		675,587
2009 Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized		$ 500,000	$ 300,000	200,000
Number of stock units awarded		21,535	16,004
Number of stock units forfeited		528	495
Number of stock units outstanding		60,182	44,391
2009 Equity Incentive Plan [Member] | Deferred Stock Units [Member] | Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized		$ 100,000	$ 100,000	$ 200,000
Number of stock units outstanding		26,991	24,441
Number of stock units outstanding estimated fair value		$ 2,000,000	$ 800,000

Stock-Based Compensation Plan_4

Stock-Based Compensation Plans - Assumptions Used in Stock Option Plans (Detail)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rates	2.18%	1.74%	1.89%
Expected life	4 years 9 months 18 days	4 years 7 months 6 days	4 years 7 months 6 days
Expected volatility	33.00%	34.00%	37.00%
Dividend yield	0.00%	0.00%	0.00%

Stock-Based Compensation Plan_5

Stock-Based Compensation Plans - Schedule of Stock Option Activity (Detail) - $ / shares	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares Outstanding, Beginning balance	1,001,905	827,325	1,118,008
Number of Shares, Granted	269,961	229,039	241,582
Number of Shares, Exercised	(450,495)	(6,819)	(437,850)
Number of Shares, Forfeited and expired	(110,825)	(47,640)	(94,415)
Number of Shares Outstanding, Ending balance	710,546	1,001,905	827,325
Number of Shares, Exercisable	236,302
Weighted Average Exercise Price, Beginning Balance	$ 21.54	$ 21.30	$ 20.10
Weighted Average Exercise Price, Granted	34.08	24.08	20.63
Weighted Average Exercise Price, Exercised	19.46	13.89	15.68
Weighted Average Exercise Price, Forfeited and expired	30.18	30.65	31.52
Weighted Average Exercise Price, Ending balance	26.28	$ 21.54	$ 21.30
Weighted Average Exercise Price, Exercisable	$ 22.33

Stock-Based Compensation Plan_6

Stock-Based Compensation Plans - Schedule of Restricted Stock Awards Activity (Detail) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning balance	67,917	33,133	27,775
Number of Shares, Granted	56,244	51,559	20,108
Number of Shares, Vested	(28,717)	(14,497)	(12,311)
Number of Shares, Forfeited	(10,020)	(2,278)	(2,439)
Number of Shares, Ending balance	85,424	67,917	33,133
Weighted Average Grant Price, Beginning balance	$ 23.98	$ 20.96	$ 22.12
Weighted Average Grant Price, Granted	34.38	25.12	20.14
Weighted Average Grant Price, Vested	23.78	21.10	22.19
Weighted Average Grant Price, Forfeited	29.10	25.12	21.17
Weighted Average Grant Price, Ending balance	$ 30.30	$ 23.98	$ 20.96

Stock-Based Compensation Plan_7

Stock-Based Compensation Plans - Schedule of Fair Value at the Date of Grant (Detail)	12 Months Ended
	Sep. 30, 2018shares
Fiscal 2016 (2016 - 2018) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	11,910
Target Shares	59,548
Maximum Shares	119,096
Fiscal 2017 (2017 - 2019) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	9,352
Target Shares	46,758
Maximum Shares	93,516

Revolving Credit Facility - Add

Revolving Credit Facility - Additional Information (Detail) - Revolving Credit Facility [Member] - USD ($)	12 Months Ended
	Sep. 30, 2018	Mar. 29, 2018
Line Of Credit Facility [Line Items]
Revolving credit facility amount	$ 30,000,000
Line of credit facility expiration date	Nov. 1, 2019
Outstanding balance		$ 0

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Taxes from Continuing Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Current (benefit) provision:
U.S. Federal	$ (890)	$ 2,125	$ 6,550
U.S. State	51	(72)	250
International	41	54	(98)
Total current (benefit) provision	(798)	2,107	6,702
Deferred (benefit) provision:
U.S. Federal	(2,006)	1,085	169
U.S. State	(271)	(85)	(43)
International			135
Total deferred (benefit) provision	(2,277)	1,000	261
Income tax (benefit) provision	$ (3,075)	$ 3,107	$ 6,963

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Line Items]
U.S. federal statutory tax rate	21.00%			24.50%	35.00%	35.00%
Discrete tax expense		$ 1,200,000	$ 1,600,000
Increase (Decrease) in deferred tax assets				$ 960,000	$ 665,000	$ (2,500,000)
Excess tax benefits (shortfalls) related to stock based compensation expense				2,000,000	(200,000)	600,000
Deferred tax asset valuation allowance				$ 4,541,000	4,511,000
Net operating loss carryforwards, remaining period				9 years
Unrecognized tax benefits excluding interest and penalties that would impact effective tax rate				$ 1,400,000	1,200,000	1,200,000
Liability for unrecognized tax benefits to change significantly in the next 12 months				400,000	500,000	600,000
Undistributed earnings in foreign subsidiaries				0	$ 0
Federal and State [Member] | 2033 [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards				$ 1,300,000
Net operating loss carryforwards, beginning of expiration year				2,033
Federal and State [Member] | 2022 [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards				$ 300,000
Net operating loss carryforwards, beginning of expiration year				2,022
Ireland and Luxembourg [Member] | Creagh Medical Ltd [Member]
Income Tax Disclosure [Line Items]
Net operating loss carryforwards				$ 3,200,000
R&D Credit Carryforwards [Member] | Federal and State [Member] | 2029 [Member]
Income Tax Disclosure [Line Items]
Tax credit carryforwards				$ 1,900,000
Tax credit carryforward, beginning of expiration year				2,029
In Vitro Diagnostics [Member]
Income Tax Disclosure [Line Items]
Capital losses generated						7,500,000
Increase (Decrease) in deferred tax assets						$ (2,600,000)

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation Difference of Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Amount at statutory U.S. federal income tax rate	$ (1,845)	$ 2,461	$ 5,932
Change because of the following items:
State income taxes, net of federal benefit	(724)	(13)	142
Stock-based compensation	(2,063)	330	(607)
Valuation allowance change	960	665	(2,500)
Tax reserve change	158	(52)	258
Federal manufacturing deduction		(313)	(280)
U.S. Federal and foreign research and development credits	(1,710)	(706)	(571)
Gain on strategic investment and corporate subsidiary			2,630
Foreign rate differential	371	948	622
Acquisition-related transaction costs			768
Contingent consideration expense (gain)	165	(45)	522
Unrealized foreign currency exchange (gain) loss on contingent consideration obligation	(23)	170
Federal and state rate change	1,582
Other	54	(338)	47
Income tax (benefit) provision	$ (3,075)	$ 3,107	$ 6,963

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Taxes (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Depreciable assets	$ (1,019)	$ (3,335)
Accruals and reserves	1,308	1,123
Stock-based compensation	1,798	3,370
Impaired strategic investments	1,687	2,701
NOL carryforwards	4,637	3,627
U.S. Federal and state R&D credits	1,896	242
Other	538	810
Valuation allowance	(4,541)	(4,511)
Total deferred tax assets	$ 6,304	$ 4,027

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Beginning of fiscal year	$ 1,481	$ 1,508	$ 1,248
Increases in tax positions for prior years	61	8	77
Decreases in tax positions for prior years		(35)	(21)
Increases in tax positions for current year	735	216	365
Settlements with taxing authorities	(613)
Lapse of the statute of limitations	(105)	(216)	(161)
End of fiscal year	$ 1,559	$ 1,481	$ 1,508

Defined Contribution Plan - Add

Defined Contribution Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Defined Contribution Plan Disclosure [Line Items]
Contribution expense	$ 0.7	$ 0.7	$ 0.3
U.S. [Member] | 401 (K) Retirement and Savings Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Percentage of employee contributions	50.00%
Percentage of employee eligible compensation	6.00%
Ireland [Member] | Defined Contribution PRSA Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Percentage of employee contributions	8.00%
Percentage of employee eligible compensation	6.00%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended	3 Months Ended	12 Months Ended				49 Months Ended
	Nov. 30, 2017USD ($)ft²	Jun. 30, 2018USD ($)	Sep. 30, 2018USD ($)€ / $shares	Sep. 30, 2018EUR (€)shares	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Dec. 31, 2023USD ($)
Commitments And Contingencies [Line Items]
Additional shares of common stock to stockholders | shares			480,059	480,059
License agreement commencement date			2006-03	2006-03
Annual minimum payments for licenses			$ 13,997,000		$ 11,422,000	$ 10,908,000
Exchange rate relating to license payment | € / $			1.1602
Future minimum payments associated with license			$ 2,100,000
Rent expense related to operating leases			500,000		100,000	$ 100,000
Acquired in-process research and development			7,888,000
Other long-term liabilities			5,720,000		$ 1,938,000
Eden Prairie Minnesota [Member]
Commitments And Contingencies [Line Items]
Square feet of office and R&D facility | ft²	36,000
Contractual obligations	$ 4,000,000
Operating lease agreement term	10 years
Operating lease agreement commencement date	2018-05
CRO [Member]
Commitments And Contingencies [Line Items]
Contractual obligation to be paid			13,200,000
Minimum [Member] | CRO [Member]
Commitments And Contingencies [Line Items]
Contractual obligation due in next several years			32,000,000
Maximum [Member] | CRO [Member]
Commitments And Contingencies [Line Items]
Contractual obligations			20,000,000
Contractual obligation due in next several years			40,000,000
License [Member]
Commitments And Contingencies [Line Items]
Annual minimum payments for licenses			$ 232,000	€ 200,000
Patents [Member]
Commitments And Contingencies [Line Items]
Patent expiry date			2027-09	2027-09
Intellectual Property [Member] | Embolitech LLC [Member]
Commitments And Contingencies [Line Items]
Payments to acquire intellectual property assets		$ 7,900,000	$ 5,000,000
Contingent payments upon achievement of regulatory milestones			2,000,000
Acquired in-process research and development			7,900,000
Other long-term liabilities			2,900,000
Intellectual Property [Member] | Embolitech LLC [Member] | Scenario Forecast [Member]
Commitments And Contingencies [Line Items]
Estimated additional payment to acquire intellectual property assets							$ 3,500,000
Selling, general and administrative [Member]
Commitments And Contingencies [Line Items]
Claim accrual recorded in selling, general and other administrative expenses			1,000,000
Other Accrued Liabilities [Member]
Commitments And Contingencies [Line Items]
Claim accrual recorded in other accrued liabilities			$ 1,000,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Annual Commitments Pursuant to Operating Lease Agreements (Detail) $ in Thousands	Sep. 30, 2018USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,019	$ 443
2,020	452
2,021	396
2,022	391
2,023	399
Thereafter	1,933
Total minimum lease payments	$ 4,014

Reportable Segment Informatio_2

Reportable Segment Information - Additional Information (Detail)	12 Months Ended
	Sep. 30, 2018SegmentSource
Segment Reporting [Abstract]
Number of operating segments | Segment	2
Number of primary sources of revenue | Source	2

Reportable Segment Informatio_3

Reportable Segment Information - Segment Revenue, Operating Income and Depreciation and Amortization (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Total revenue	$ 23,038	$ 22,227	$ 19,058	$ 17,013	$ 20,058	$ 17,790	$ 17,503	$ 17,761	$ 81,336	$ 73,112	$ 71,366
Operating (loss) income	$ (2,441)	$ (6,250)	$ 525	$ (633)	$ 415	$ 1,743	$ 1,677	$ 3,268	(8,799)	7,103	16,859
Depreciation and amortization									6,431	5,555	4,873
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating (loss) income									141	15,195	24,090
Operating Segments [Member] | Medical Device [Member]
Segment Reporting Information [Line Items]
Total revenue									60,513	53,983	53,202
Operating (loss) income									(8,478)	6,902	16,975
Depreciation and amortization									5,376	4,453	3,261
Operating Segments [Member] | In Vitro Diagnostics [Member]
Segment Reporting Information [Line Items]
Total revenue									20,823	19,129	18,164
Operating (loss) income									8,619	8,293	7,115
Depreciation and amortization									394	412	789
Corporate [Member]
Segment Reporting Information [Line Items]
Operating (loss) income									(8,940)	(8,092)	(7,231)
Depreciation and amortization									$ 661	$ 690	$ 823

Reportable Segment Informatio_4

Reportable Segment Information - Revenue from Major Customers (Detail) - Revenue [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Medtronic [Member]
Revenue, Major Customer [Line Items]
Percentage of revenue	16.00%	18.00%	25.00%
Abbott [Member]
Revenue, Major Customer [Line Items]
Percentage of revenue	11.00%

Reportable Segment Informatio_5

Reportable Segment Information - Geographic Revenue and Long-lived Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, including property and equipment and intangible assets net of accumulated depreciation and amortization	$ 26,652	$ 20,949
Ireland [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, including property and equipment and intangible assets net of accumulated depreciation and amortization	$ 21,174	$ 22,555
Revenue [Member] | Geographic Concentration Risk [Member] | Domestic [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Percentage of revenue	79.00%	77.00%	79.00%
Revenue [Member] | Geographic Concentration Risk [Member] | Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Percentage of revenue	21.00%	23.00%	21.00%

Quarterly Financial Data (Una_3

Quarterly Financial Data (Unaudited) - Summary of Unaudited Quarterly Results (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Quarterly Financial Information Disclosure [Abstract]
Total revenue	$ 23,038	$ 22,227	$ 19,058	$ 17,013	$ 20,058	$ 17,790	$ 17,503	$ 17,761	$ 81,336	$ 73,112	$ 71,366
Operating (loss) income	(2,441)	(6,250)	525	(633)	415	1,743	1,677	3,268	(8,799)	7,103	16,859
Net (loss) income	$ (1,753)	$ (2,682)	$ 1,534	$ (1,556)	$ 400	$ 720	$ 506	$ 2,300	$ (4,457)	$ 3,926	$ 9,985
Basic net (loss) income per share	$ (0.13)	$ (0.20)	$ 0.12	$ (0.12)	$ 0.03	$ 0.05	$ 0.04	$ 0.17	$ (0.34)	$ 0.30	$ 0.77
Diluted net (loss) income per share	$ (0.13)	$ (0.20)	$ 0.11	$ (0.12)	$ 0.03	$ 0.05	$ 0.04	$ 0.17	$ (0.34)	$ 0.29	$ 0.76

Quarterly Financial Data (Una_4

Quarterly Financial Data (Unaudited) - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended				9 Months Ended	12 Months Ended
	Dec. 31, 2017	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Quarterly Financial Data [Line Items]
Discrete tax expense				$ 1,200		$ 1,600
U.S. federal statutory tax rate	21.00%						24.50%	35.00%	35.00%
Royalties and License Fees [Member]
Quarterly Financial Data [Line Items]
License fee revenue							$ 35,424	$ 31,787	$ 33,203
Royalties and License Fees [Member] | Abbott [Member]
Quarterly Financial Data [Line Items]
License fee revenue			$ 4,400
Intellectual Property [Member] | Embolitech LLC [Member]
Quarterly Financial Data [Line Items]
Payments to acquire intellectual property assets		$ 7,900					$ 5,000
Intellectual Property [Member] | Royalties and License Fees [Member]
Quarterly Financial Data [Line Items]
License fee revenue					$ 1,100